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ABSTRACT

Engle, Staci E. Ph.D., Purdue University, May 2016. Studies of nicotinic acetylcholine
receptors containing α4 and α6 subunits in nicotine-induced synaptic plasticity in brain
reward areas. Major Professor: Ryan Drenan.

Tobacco addiction is a serious threat to public health in the United States and abroad, and
development of new therapeutic approaches is a major priority. Nicotine, the primary
psychoactive compound in tobacco smoke, activates and/or desensitizes nicotinic
acetylcholine receptors (nAChRs) throughout the brain. nAChRs in ventral tegmental area
(VTA) dopamine (DA) neurons are crucial for the rewarding and reinforcing properties of
nicotine. Nicotine causes cellular changes in VTA DA neurons, including the enhancement
of AMPA receptor (AMPAR) function. This enhancement sensitizes the VTA to excitatory
input and promotes drug seeking in animal models. However, which nAChR subtype(s)
are responsible for initiating these cellular changes is poorly understood. nAChRs
containing the α6 subunit (α6* nAChRs) are highly and selectively expressed in DA
neurons in the VTA. Therefore, we hypothesized that activation of α6* nAChRs is
sufficient to enhance AMPAR function on the surface of VTA DA neurons. To test this, we
studied mice expressing hypersensitive, gain-of-function α6 nAChRs (α6L9S mice). We
found that low concentrations of nicotine could act selectively through α6* nAChRs to
enhance the function of AMPARs on the surface of VTA DA neurons. Through

xi
pretreatment with pharmacological inhibitors, we found that NMDA receptors, as well as
Ca2+/calmodulin dependent protein kinase II, are also required for this effect. We
subsequently expanded these studies to include alcohol because of the high rate of
tobacco and alcohol co-abuse. Just as with nicotine, we found that low concentrations of
ethanol were sufficient to enhance AMPAR function on VTA DA neurons of α6L9S mice.
Because ethanol and nicotine both modulate AMPAR function in a manner involving α6*
nAChRs, we tested the hypothesis that low concentrations of ethanol and nicotine
combine to modulate AMPAR function. Remarkably, co-incubation of α6L9S brain slices
in concentrations of ethanol and nicotine that are sub-threshold when incubated alone
resulted in robust enhancement of AMPAR function. Within the VTA, α6 nAChR subunits
form nAChRs with and without the α4 nAChR subunit. Therefore, we studied the
contribution of α4 nAChR subunits to nicotine-elicited changes in VTA synaptic plasticity.
To address this, we removed α4 nAChR subunits from the VTA of adult mice by injecting
viral vectors directing expression of Cre recombinase into the VTA of mice with loxP sites
flanking the α4 subunit gene. We found that nicotine no longer increases AMPAR function
when α4 nAChR subunits are removed from the VTA, indicating a role of nAChRs that
contain both α4 and α6 nAChR subunits in VTA synaptic plasticity. Interestingly, we also
saw that removing α4 subunits from the VTA of adult mice increases the excitability of
VTA DA neurons. We hypothesized that removal of α4* nAChRs from GABAergic neurons
in the VTA results in less tonic inhibition of VTA DA neurons. To test this we measured
spontaneous inhibitory postsynaptic currents (IPSCs) on VTA DA neurons. Indeed, we saw
that the instantaneous frequency of IPSCs was significantly reduced when α4 nAChR

xii
subunits are removed from the VTA. Overall, these studies highlight the importance of
α4α6* nAChRs in the initiation of cellular changes that play a role in addiction to nicotine,
suggesting α4α6* nAChRs may be a promising target for future smoking cessation
pharmacotherapies.
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INTRODUCTION

1.1

Tobacco Addiction

Tobacco use is a major health problem in the United States. It results in numerous health
complications including lung cancer, ischemic heart disease, and chronic obstructive
pulmonary disease, among others. Tobacco use is the leading cause of preventable death
(NCCD 2014). It results in nearly 6 million deaths per year worldwide and is predicted to
cause over 8 million deaths per year by 2030 (Mathers & Loncar 2006). Even though there
are numerous health benefits to quitting tobacco use, nicotine, an addictive compound
in tobacco, makes quitting difficult. Nearly 70% of smokers have the desire to quit, yet
over 95% of attempts to quit fail within the first year of abstinence (CDC 1993, CDC 2002).
Many people relapse quickly because of nicotine withdrawal symptoms, just a few of
which include tobacco cravings, irritability, anxiety, insomnia, and nausea (West et al
2006). People also relapse in times of stress and to prevent the weight gain that
sometimes occurs when smokers quit (McKee et al 2011, Mineur et al 2011).
While nearly 20% of the general population are smokers, an even higher percentage of
people with mental illnesses smoke cigarettes. Around 50% of people with depression
smoke cigarettes (Pratt & Brody 2010) and greater than 60% of schizophrenics smoke
cigarettes. This increase may be explained by the possibility that smoking helps them to
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overcome cognitive deficits as well as alleviate extrapyramidal symptoms caused by their
medication (Sagud et al 2009).
For all of the reasons above, development of effective smoking cessation
pharmacotherapies is a major priority. Current options include over-the-counter nicotine
replacement therapies and prescription medications. One of the most successfully used
drugs is Chantix, or varenicline. However, only 23% of people prescribed Chantix are still
abstinent 1 year after quitting (Knight et al 2010). It also has the potential to cause several
side effects ranging from mild to severe (Ebbert et al 2010, Hays et al 2008). Therefore,
the overarching goal of our research is to better understand the mechanisms through
which nicotine acts in order to identify targets for more specific and efficacious smoking
cessation pharmacotherapies.
1.2

Nicotinic Acetylcholine Receptors

Nicotine is a tertiary amine alkaloid. It exerts its addictive properties through its actions
on nicotinic acetylcholine receptors (nAChRs) (Laviolette & van der Kooy 2004). The
endogenous ligand of nAChRs is acetylcholine (ACh). They are a member of the cys-loop
family of ligand-gated ion channels that also includes gamma-aminobutyric acid (GABA),
serotonin, and glycine receptors. nAChRs are composed of five subunits arranged to form
a central, ion-conducting pore. Each subunit consists of four transmembrane segments,
two intracellular loops, and extracellular N- and C-terminal domains (Dani & Bertrand
2007). The N-terminal domain contains the two cysteine residues of the cys-loop.
Neuronal nAChRs are composed of  and subunits and can be either homomeric or
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heteromeric. Homomeric nAChRs are composed of all  subunits while heteromeric
nAChRs are composed of both  and  subunits. Heteromeric receptors may contain
either 3  and 2  subunits or 2  and 3  subunits (Itier & Bertrand 2001). Currently, 11
different neuronal nAChR subunits have been identified in mammals: 2-7, 9, 10,
and 2-4. The 8 nAChR subunit is found in avian species but not mammals. 7 nAChR
subunits can form homomeric nAChRs while 2-6 and 2-4 nAChR subunits combine
to form functional heteromeric nAChRs (Le Novere et al 2002, Millar & Gotti 2009).
However, 5 and 3 nAChR subunits are considered auxiliary subunits because while they
are able modulate channel function, they do not form binding sites (Cui et al 2003, Drenan
et al 2008b, Fowler et al 2011). This leads to a diverse array of possible nAChR subtypes.
Different subunits combine to form nAChR subtypes with differing pharmacological
properties (Le Novere et al 2002). 42* (* indicates the possibility of other subunits
present in the pentamer) and 7 nAChRs are the most abundant subtypes and are
expressed widely throughout the brain (Millar & Gotti 2009).
nAChRs have three conformational states: open, closed, and desensitized. In the absence
of a ligand, nAChRs remain in the closed state. Upon ligand binding, channels open. The
orthosteric binding site is formed at the interface of the N-termini of two adjacent 
subunits in homomeric nAChRs or between that of a  and  subunit in heteromeric
nAChRs. Therefore, homomeric nAChRs contain five binding sites while heteromeric
nAChRs have just two. Na+, K+, and Ca2+ can flow through nAChRs in the open state. The
degree of Ca2+ permeability varies depending on the nAChR subtype. The M2
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transmembrane domain from each of the 5 subunits line the pore and help to determine
ion selectivity (Corringer et al 2000). nAChRs can be found both presynaptically on
terminals and postsynaptically on cell bodies. Therefore, nAChR activation can result in
cell depolarization and neurotransmitter release (Dani & Bertrand 2007). nAChRs that
are desensitized are in a non-conducting state (Picciotto et al 2008).
1.3

Mesolimbic Reward Pathway

Most important to tobacco addiction, several nAChR subtypes are expressed in the
mesolimbic reward pathway. The mesolimbic reward pathway consists of dopamine (DA)
neurons located in the ventral tegmental area (VTA) and their projections to the nucleus
accumbens (NAc) (Laviolette & van der Kooy 2004)(Figure 1). Drugs of abuse, including
nicotine, result in a rise in DA release in the NAc (Di Chiara & Imperato 1988). Lesions of
the mesolimbic DA system, as well as DA receptor antagonists, reduce nicotine selfadministration in rats (Corrigall & Coen 1991, Corrigall et al 1992). More specifically,
nAChRs within the VTA are responsible for the reinforcing properties of nicotine, as shown
by reduced self-administration following intra-VTA infusion of nAChR antagonists
(Corrigall et al 1994). The VTA is located in the ventral midbrain. In addition to the
mesolimbic pathway, the VTA is also part of the mesocortical pathway. VTA DA neurons
in this pathway send projections to the prefrontal cortex (PFC) (Laviolette & van der Kooy
2004)(Figure 1). Along with DA neurons, there are also GABAergic interneurons in the
VTA which provide inhibitory input to DA neurons (Figure 1). Glutamatergic terminals
that provide excitatory neurotransmission in the VTA arise primarily from the PFC, bed
nucleus of the stria terminalis, amygdala, pedunculopontine tegmental nucleus (PPTg),
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and the lateral dorsal tegmental nucleus (LDTg) (Mao & McGehee 2010)(Figure 1).
Additionally, the VTA receives cholinergic and GABAergic input from the PPTg and LDTg
(Mao & McGehee 2010) (Figure 1). These cholinergic inputs help regulate burst firing of
VTA DA neurons (Lanca et al 2000). In addition to modulating reward, the cholinergic
system is also thought to play a role in regulating sleep cycles and memory formation
(Mark et al 2011, McKinney & Jacksonville 2005).
The VTA is emerging as a heterogeneous structure. DA neurons within different regions
of the VTA have different electrophysiological properties and project to different regions
of the brain. For example, DAergic neurons in the lateral VTA project to the NAc shell
while those in the medial VTA project to the NAc core and PFC (Lammel et al 2014). In
addition, systemically administered nicotine preferentially activates DA neurons in the
posterior VTA (bregma: −3.28 to −3.80 mm) over the anterior or tail VTA (Zhao-Shea et al
2011).

6

Figure 1. Simplified illustration of dopaminergic, cholinergic, glutamatergic, and
GABAergic circuity projecting to and from the VTA within the mouse brain.
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1.4

nAChRs in the VTA

Physiologically relevant concentrations of nicotine (around 100-500 nM) activate and/or
desensitize nAChRs (Picciotto et al 2008, Pidoplichko et al 1997). Nicotine acts through
nAChRs to enhance firing of VTA DA neurons (Calabresi et al 1989) and increase DA
release in the NAc (Di Chiara & Imperato 1988). Within the VTA, nAChRs are located on
several cell types. nAChRs are expressed on DA cell bodies, glutamatergic terminals, and
GABAergic interneurons (Marubio et al 2003). DA cell bodies express heteromeric
nAChRs and a subset also express homomeric α7 nAChRs (Azam et al 2002). nAChRs
containing the α6 nAChR subunit are selectively expressed on DA neurons in the VTA
(Drenan et al 2008a, Le Novere et al 1996, Mackey et al 2012). GABA interneurons
provide inhibitory inputs onto VTA DA neurons and express mainly α4β2* nAChRs (Klink
et al 2001, Mansvelder et al 2002, Nashmi et al 2007). However, nicotine only briefly
activates these receptors before desensitization occurs. Therefore, after a transient
increase, inhibitory neurotransmission to VTA DA neurons in ultimately decreased
(Mansvelder et al 2002). Glutamatergic terminals that synapse onto VTA DA neurons
express homomeric α7 nAChRs (Jones & Wonnacott 2004). Nicotine activates nAChRs on
glutamatergic terminals and therefore enhances excitatory neurotransmission to VTA DA
neurons (Mansvelder & McGehee 2000).
While there are several possible heteromeric nAChR subtypes in the VTA, it is important
to understand which particular subtype(s) are necessary and/or sufficient for nicotine
reinforcement and reward. 2* nAChRs are crucial for nicotine’s reinforcing properties

8
(Picciotto et al 1998). Nicotine does not result in an increase in DA release in 2 knockout
(KO) mice and 2KO mice do not self-administer nicotine (Picciotto et al 1998, Pons et al
2008). Furthermore, in electrophysiology studies done in brain slices from 2KO mice,
DA neurons do not respond to puff application of nicotine. This can be explained by
radioligand binding studies which reveal that high affinity nicotine binding sites are
completely absent in 2KO mice (Picciotto et al 1995, Zoli et al 1998).
The main high-sensitivity nAChRs in the VTA include those containing 4 and/or 6
subunits (Salminen et al 2007, Salminen et al 2004). Like the 2 nAChR subunit, 4 and
6 nAChR subunits are also necessary for nicotine self-administration (Pons et al 2008).
Selective re-expression of these subunits into the VTA shows that 4, 6, and 2 nAChR
subunit expression specifically within the VTA drives nicotine reinforcement (Maskos et
al 2005, Pons et al 2008). Because nAChR function in VTA DA neurons is absent in 2KO
mice, 4 and 6 subunits must co-assemble with the 2 subunit to form functional
receptors (Picciotto et al 1998). Further studies have concluded that VTA DA neurons
express nAChRs with the following compositions: (4)3(2)2, (4)2(2)3, 452, 242,
423, 62, 623, 642, and 4623 (Gotti et al 2010, Gotti et al 2005,
Salminen et al 2007). 4623 nAChRs have the highest affinity to nicotine with an EC50
of around 230 nM (Salminen et al 2007) and make up approximately 20% of the 2*
nAChR binding sites in VTA DA neurons (Gotti et al 2010). -conotoxin MII (CtxMII) is a
competitive antagonist selective for 6* nAChRs (Cartier et al 1996, Champtiaux et al
2002) and dihydro--erythroidine (DHE) is a competitive antagonist moderately
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selective for 4* nAChRs (Harvey et al 1996). Nevertheless, there are currently no
antagonists that distinguish between 46*, (non-6)4*, and (non-4)6* nAChRs,
making their differential effects difficult to study. In addition to the roles of 4* and 6*
nAChRs in the reinforcing and rewarding properties of nicotine discussed below, there is
evidence for the involvement of 46* nAChRs as well (Drenan et al 2010, Liu et al 2012,
Zhao-Shea et al 2011).
The involvement of 4* nAChRs in the reinforcing properties of nicotine is not only
demonstrated by the absence of nicotine self-administration in 4KO mice (Pons et al
2008), but also by wild-type (WT) mice that fail to self-administer nicotine after given an
intra-VTA infusion of DHE to block 42* nAChRs in the VTA (Corrigall et al 1994). 
nAChRs contribute to the rewarding properties of nicotine as well. Selectively activating
4* nAChRs will condition a place preference to nicotine (Tapper et al 2004) and 4KO
mice do not show a place preference to nicotine (Sanjakdar et al 2015). Moreover, 4
nAChRs specifically on DA neurons are necessary for nicotine reward (McGranahan et al
2011). At the cellular level, nicotine does not significantly activate VTA DA neurons in
4KO mice as compared to WT mice (Liu et al 2012, Zhao-Shea et al 2011).
6* nAChRs are unique in that they are expressed in a limited number of brain regions,
unlike 4 and 2 subunits that are widely expressed throughout the brain (Champtiaux
et al 2003, Marubio et al 2003, Nashmi et al 2007, Ross et al 2000). They are mainly found
in catecholaminergic neurons, and most notably in the VTA, substantia nigra pars
compacta, locus coeruleus, retinal ganglion cells, and their projection areas (Champtiaux
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et al 2002, Cox et al 2008, Gotti et al 2005, Hill et al 1993, Le Novere et al 1996, Lena et al
1999, Mackey et al 2012, Whiteaker et al 2000). As discussed above, 6KO mice do not
self-administer nicotine (Pons et al 2008). In addition, in WT mice, intra-VTA CtxMII
infusions block nicotine self-administration, as well as DA release in the NAc (Gotti et al
2010). 6KO mice do not find nicotine rewarding at a dose that is sufficient to condition
a place preference in WT mice (Sanjakdar et al 2015). CtxMII infusions further support
a role for 6* nAChRs in nicotine reward, because it dose-dependently decreases nicotine
place preference in WT mice (Sanjakdar et al 2015). Likewise, selectively activating 6*
nAChRs can condition a place preference to nicotine (Drenan et al 2012). Their restricted
expression and their key role in the rewarding and reinforcing properties of nicotine make
6* nAChRs an attractive option to selectively target with nicotine cessation drugs.
1.5

Long-Term Potentiation

Long-term potentiation (LTP) is the strengthening of synapses for an extended period of
time following stimulation. LTP is measured by a protocol that pairs presynaptic
stimulation with postsynaptic depolarization. The opposite of LTP is long-term depression
(LTD), or the weakening of synapses. The ability of neurons to increase and decrease the
strength of synapses over time is referred to as synaptic plasticity or changes in synaptic
strength (Kauer & Malenka 2007).
Both 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl) propanoic acid (AMPA) receptors
(AMPARs) and N-methyl-D-aspartate (NMDA) receptors (NMDARs) are key players in
glutamatergic synaptic plasticity. These receptors belong to the family of ionotropic
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glutamate receptors, which also includes kainate receptors. AMPARs are tetramers
composed of a combination of AMPA-type ionotropic glutamate receptor (GluR) 1, GluR2,
GluR3, and GluR4 subunits.

Glutamate receptors are activated by the binding of

endogenous glutamate, or exogenous AMPA. Upon activation the pore opens and allows
cations into the cell. AMPARs containing the GluR2 subunit are impermeable to Ca2+.
AMPARs lacking the GluR2 subunit are permeable to both Na+ and Ca2+ (Isaac et al 2007).
NMDARs are also tetramers. They are composed of varying combinations of NR1, NR2A,
NR2B, NR2C, NR2D, NR3A and NR3B subunits. They contain a central pore that is voltagedependently blocked by Mg2+.

When cells expressing NMDARs are sufficiently

depolarized, the Mg2+ block is relieved. NMDARs are highly Ca2+ permeable so once the
cell is depolarized and the Mg2+ block is removed, binding of NDMA or glutamate results
in Ca2+ influx into the cell (Cull-Candy et al 2001).
The most widely studied form of LTP is NMDAR-dependent LTP (Malenka & Bear 2004).
This form of LTP requires the activation of NMDARs. Therefore, the postsynaptic cell must
be sufficiently depolarized in order for the Mg2+ block to be removed. When the Mg2+
block is removed, glutamate released by the presynaptic cell activates NMDARs, resulting
in Ca2+ entry into the postsynaptic cell. The rise in Ca2+ levels leads to intracellular
signaling, including activation of calcium/calmodulin-dependent protein kinase II
(CaMKII), and ultimately insertion of AMPARs into the cell membrane at the synapse on
the postsynaptic cell (Kauer & Malenka 2007, Malenka & Bear 2004). Other types of LTP
exist in addition to NMDAR-dependent LTP, such as presynaptic LTP (Kauer & Malenka
2007).
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1.6

Synaptic Plasticity in the VTA

LTP is classically associated with learning and memory in the hippocampus (Malenka &
Bear 2004). However, LTP can be induced in VTA DA neurons as well (Bonci & Malenka
1999). Excitatory synapses on VTA DA neurons, but not excitatory synapses on VTA GABA
neurons, can be potentiated by a standard LTP pairing protocol (Bonci & Malenka 1999).
LTP in VTA DA neurons is NMDAR-dependent and does not involve metabotropic
glutamate receptors, like some other forms of LTP in the hippocampus (Bonci & Malenka
1999). LTD can also be observed on VTA DA neurons (Thomas et al 2000). These results
show that stimulation of the VTA can lead to long-term alterations in the synaptic strength
of synapses on DA neurons.
Increased DA release in the NAc long outlives the actions of nicotine on nAChRs on VTA
DA neurons. The concentration of nicotine achieved by smokers rapidly desensitizes
nAChRs on VTA DA neurons (Pidoplichko et al 1997). Nevertheless, nicotine causes
increased DA levels in the NAc for an hour or more in rodent models (Di Chiara & Imperato
1988). Therefore, additional cellular changes must occur in VTA DA neurons following
nicotine exposure to maintain enhanced DA release. This long-lasting enhancement of
DA release is suggested to be a result of increased glutamatergic synaptic plasticity in the
VTA (Kauer & Malenka 2007, Wolf et al 2004). Glutamatergic signaling in the VTA plays an
important role in DA release in the NAc. Stimulating the PFC, the main source of
glutamatergic inputs to the VTA, results in enhanced burst firing of VTA DA neurons and
increased DA release in the NAc (Murase et al 1993). Furthermore, blocking NMDARs with
an intra-VTA infusion of a NMDAR antagonist will dose-dependently decrease nicotine-
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enhancement of DA release in the NAc of rats (Schilström et al 1997). Thus, strengthening
of glutamatergic synapses on VTA DA neurons could support prolonged DA release.
Mansvelder and McGehee found for the first time that exposing brain slices to nicotine
leads to the induction of LTP on VTA DA neurons (Mansvelder & McGehee 2000). Pairing
a brief 200 second nicotine application with a postsynaptic depolarization is sufficient to
increase the amplitude of evoked excitatory postsynaptic currents (EPSCs) for as long as
40 minutes. Nicotine-induced LTP was prevented by both methyllycaconitine (MLA; 7
nAChR antagonist) and D-2-amino-5-phosphonopentanoic acid (AP-5; competitive
NMDAR antagonist; also commonly known as APV), indicating the mechanism is mediated
by 7 nAChRs and NMDARs (Mansvelder & McGehee 2000).
Following this discovery, it was also found that in vivo drug exposure can induce LTP-like
changes in VTA DA neurons. This was first observed with a single exposure to cocaine
(Ungless et al 2001) and then generalized to other drugs of abuse, including nicotine (Saal
et al 2003). Because drugs were given in vivo, the classical method of measuring LTP had
to be altered. Therefore, to measure changes in synaptic strength, these studies
compared AMPA receptor mediated currents to NMDA receptor mediated currents
(AMPA/NMDA ratios) as a surrogate measure of LTP. It is important to note that
AMPA/NMDA ratios are not similarly increased after exposure to psychoactive drugs that
are not addictive (Saal et al 2003). These drug-induced synaptic changes are correlated
with addiction-related behaviors, such as the acquisition of self-administration and
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behavioral sensitization (Borgland et al 2004, Chen et al 2008, Dong et al 2004, Luscher &
Malenka 2011)
1.7

Mechanisms of Nicotine-Evoked Synaptic Plasticity in the VTA

To better understand nicotine-induced increases in synaptic strength, various aspects
such as the time course, which nAChR subtypes are involved, and intracellular signaling
mechanisms have been studied. Changes in glutamatergic synaptic strength on VTA DA
neurons have been observed after both in vivo nicotine exposure via nicotine injections
and ex vivo via incubation of naïve brain slices in nicotine. The duration of nicotine
exposure determines whether increases in AMPA/NMDA ratios occur and how long they
last. Several studies have demonstrated that increases in AMPA/NMDA ratios are seen
24 hours after a nicotine injection (Baker et al 2013, Gao et al 2010, Placzek et al 2009,
Saal et al 2003). Wu and colleagues performed further experiments to look at additional
time points (Gao et al 2010). They found that waiting 10 minutes after the nicotine
injection was not sufficient to see increases in AMPA/NMDA ratios. However, after a
single nicotine injection, increases in AMPA/NMDA ratios are seen after one hour, and
last at least 72 hours, but do not persist for as long as 5 days. Multiple nicotine injections
(once daily for seven days) result in increased AMPA/NMDA ratios for as long as 8 days
after the last injection (Gao et al 2010).
Studies using naïve brain slices have also found that the slices must be incubated in
nicotine for a sufficient amount of time before changes in AMPA/NMDA ratios are
observed (Jin et al 2011, Mao et al 2011). While one study reports that a 10 minute
nicotine incubation was not sufficient to increase AMPA/NMDA ratios (Jin et al 2011),
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another saw significant changes with after incubating slices in nicotine for just 15 minutes
(Mao et al 2011).
Not only is the length of nicotine exposure important to consider when investigating
changes in AMPAR function, but also the age of the animal at the time of nicotine
exposure. Placzek et al. found that lower doses of nicotine could increase AMPA/NMDA
ratios in young mice (postnatal days 21-35) compared to the doses required for adult mice
(postnatal days 60-90) (Placzek et al 2009). This suggests that the developing brain may
be more sensitive to nicotine-induced changes in glutamatergic synaptic plasticity on VTA
DA neurons. This could be the result of differing nAChR expression between adolescence
and adulthood.

Interestingly, there are higher levels of α6 nAChR subunit mRNA

expressed in the VTA of juvenile rats (Azam et al 2007). This makes α6* nAChRs an
interesting target to explore when investigating which nAChR subtypes are responsible
for nicotine-induced synaptic plasticity.
Understanding which nAChR subtypes nicotine acts through to increase AMPA/NMDA
ratios will lead to a better understanding of the mechanism through which glutamatergic
plasticity occurs in the VTA. Different studies have addressed this topic but it remains
unclear which nAChR subtypes are primarily involved because of conflicting results. As in
any comparison between scientific studies, differences in experimental details may
account for contrasting results. Studies exposing naïve brain slices to nicotine do not
agree on the involvement of α4β2* nAChRs (Jin et al 2011, Mao et al 2011). One group
concluded that α4β2* nAChRs are not involved because pre-incubating brain slices from
Wistar rats in DHβE, a moderately selective α4* nAChR antagonist, before nicotine
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incubation did not inhibit increases in AMPA/NMDA ratios (Jin et al 2011). A similar
experiment that instead used Sprague Dawley rats, however, found DHβE had the ability
to block nicotine-induced increases in AMPA/NMDA ratios (Mao et al 2011). Findings on
the involvement of α7 nAChRs, which are primarily found on glutamatergic terminals, are
also conflicting. One study found no increases in AMPA/NMDA ratios after pre-incubating
brain slices in MLA, a α7 nAChR antagonist (Jin et al 2011). Yet a second study using brain
slices reports no involvement of α7 nAChRs as they found MLA pre-incubation was not
able to block nicotine’s ability to increase AMPA receptor function (Mao et al 2011).
An in vivo study concluded that increases in AMPA/NMDA ratios could proceed through
activation of either α7 nAChRs or β2* nAChRs. They found that pre-injecting rats with a
α7 nAChR antagonist before giving a nicotine injection did not block increases in
AMPA/NMDA ratios, but neither did a β2 nAChR antagonist. However, increases were
prevented when both antagonists were injected together (Gao et al 2010).
In addition to studies relying on pharmacological inhibitors, genetically modified mice
have also been used as a tool to measure changes in glutamatergic synaptic plasticity. In
agreement with the results from in vivo antagonist pre-injection, nicotine injections still
resulted in increased AMPA/NMDA ratios in both α7KO and β2KO mice (Gao et al 2010).
However, a study done by Jin et al found no increases in AMPA/NMDA ratios in α7KO
mice, more in agreement with their MLA slice incubation procedure (Jin et al 2011).
No previous studies have looked at the role of α6* nAChRs in increased AMPA/NMDA
ratios. A study by Brown et al leads us to believe these receptors may of interest. They
showed that using optogenetics to selectively activate DA neurons via light stimulation is
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sufficient for enhancement of AMPA/NMDA ratios in the VTA (Brown et al 2010). Because
α6* nAChRs are selectively expressed on DA neurons in the VTA (Drenan et al 2008a,
Mackey et al 2012), their activation may be sufficient to increase AMPA/NMDA ratios as
well.
In addition to determining which nAChR subtype nicotine acts through, it is also important
to understand what circuit and molecular events downstream of nAChR activation are
involved in the enhancement of excitatory synapses on VTA DA neurons. Enhanced
AMPA/NMDA ratios could be mediated by changes in the distribution and/or composition
of AMPARs expressed on the surface of VTA DA neurons. An increase in the number of
AMPARs expressed at glutamatergic synapses would result in an increase in AMPAR
function (Kauer & Malenka 2007). Alternatively, an exchange of Ca2+ impermeable
AMPARs for Ca2+ permeable AMPARs would also enhance the AMPA mediated
component of AMPA/NMDA ratios (Luscher & Malenka 2011). AMPARs lacking the GluR2
subunit are Ca2+ permeable. Inward rectification is a hallmark of GluR2-lacking AMPARs
(Isaac et al 2007, Liu & Zukin 2007). There are some studies suggesting the presence of
inwardly-rectifying AMPARs on VTA DA neurons after nicotine exposure (Brown et al 2010,
Gao et al 2010) as well as another report that there are not (Baker et al 2013). These
contrasting results indicate that nicotine may either cause an increase in sensitivity
and/or an increase in the number of AMPARs expressed on VTA DA neurons. More work
is needed to uncover what changes are occurring at the AMPAR level following nicotine
exposure.
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There is no debate, however, on the necessity of NMDAR activation in the mechanism of
nicotine-evoked increases in AMPA/NMDA ratios. Whether it be pre-injection with MK801, a selective and non-competitive NMDAR antagonist, (Gao et al 2010) or preincubating slices in AP-5 (Mansvelder & McGehee 2000, Mao et al 2011), all studies show
NMDAR antagonists inhibit increases in glutamatergic synaptic strength.
In order for NMDARs to be activated, the neuron first must be sufficiently depolarized to
relieve the Mg2+ block present in NMDARs (Cull-Candy et al 2001). Nicotine itself leads to
depolarization of DAergic neurons (Liu et al 2012, Pidoplichko et al 1997). This may be
sufficient to remove the Mg2+ block or it may initiate other signaling events that further
contribute to DA neuron depolarization or NMDAR activation.

Nicotine results in

somatodendritic DA release (Rahman et al 2003). DA released in this manner could then
activate D5 DA receptors in the VTA, resulting in the initiation of changes in AMPA and/or
NMDA receptors, possibly through altered glutamate release (Mao et al 2011, Schilstrom
et al 2006). Several studies have investigated this through the use of D1/D5 DA receptor
antagonists. While the antagonists do not differentiate between D1 and D5 DA receptors,
the involvement of the D5 DA receptor is more likely as D1 DA receptors have not been
found in VTA DA neurons (Schilstrom et al 2006). Mao et al found that pre-incubating
slices in the D1/D5 DA receptor antagonist SCH-23390 before nicotine exposure could
abolish increases in AMPA/NMDA ratios. Further, they also found that incubating slices
in SKF 81297 (a D1/D5 DA receptor agonist) alone was sufficient to increase AMPA/NMDA
ratios (Mao et al 2011). Brown et al found a similar effect in vivo. Intra-VTA infusion of
SCH-23390 before light stimulation of VTA DA neurons blocked increases in AMPA/NMDA
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ratios (Brown et al 2010). However, another in vivo study was not consistent with those
discussed above. Gao et al found that pre-injection of a solution of SCH-23390 and
haloperidol did not block nicotine-mediated increases in AMPA/NMDA ratios (Gao et al
2010).
Because NDMAR activity is required, it is highly likely that calcium signaling plays a role in
enhanced AMPA/NMDA ratios. Therefore, calcium dependent protein kinases or
phosphatases could be required for changes in nicotine-mediated glutamatergic synaptic
plasticity.

When

activated,

calcineurin,

a

serine/threonine

phosphatase,

dephosphorylates AMPARs and NMDARs among other targets. Its activity is necessary in
the VTA for nicotine-mediated locomotor sensitization (Addy et al 2007). However, Gao
et al. found that calcineurin involvement in not necessary for nicotine-mediated increases
in AMPA/NMDA ratios, as they found that pre-injection of cyclosporine, a calcineurin
inhibitor, had no effect on increases in AMPA/NMDA ratios (Gao et al 2010). Additional
work on other calcium dependent kinases and phosphatases, such as CaMKII, will reveal
more about the role of calcium signaling in nicotine-induced increases in glutamatergic
synaptic strength in VTA DA neurons.
1.8

Nicotine and Ethanol Co-Abuse

Tobacco and alcohol co-abuse is extremely common (Bobo 1992, DiFranza & Guerrera
1990, Falk et al 2006, Grant et al 2004, Miller & Gold 1998). Alcohol consumption
increases the amount of cigarettes smoked, cigarette cravings, and the rewarding effects
experienced from smoking (Friedman et al 1991, Harrison et al 2009, Mitchell et al 1995,
Rose et al 2004). Likewise, nicotine increases the amount of alcohol consumed (Barrett et
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al 2006). The high prevalence of tobacco and alcohol co-abuse suggests that nicotine and
ethanol may have common molecular targets in the brain mediating their rewarding
effects.
1.9

Ethanol and nAChRs

Ethanol has the ability to modulate several types of ionotropic receptors including GABAA,
NMDA, and serotonin receptors (Dopico & Lovinger 2009). It is now starting to be
appreciated that ethanol modulates nAChRs as well. Several studies using heterologous
expression systems or cultured neurons suggest that ethanol potentiates or inhibits AChevoked currents depending on the subtype of nAChR expressed. In Xenopus oocytes
expressing human nAChR subunits, ethanol potentiated ACh-evoked currents from 42,
44, 22, 24 nAChRs but inhibited 7 nAChRs. The same study found ethanol did
not alter currents from 32 or 34 nAChRs (Cardoso et al 1999). In rat cultured cortical
neurons, -bungarotoxin (-BuTX) was used to distinguish 7 nAChRs from heteromeric
nAChRs (-BuTX sensitive and -BuTX insensitive, respectively). As in Xenopus oocytes,
7 nAChRs are inhibited by ethanol and heteromeric nAChRs are potentiated by ethanol
(Aistrup et al 1999).
nAChRs in vivo also indicate ethanol modulates nAChRs. Mice given mecamylamine
(MEC), a non-competitive nAChR antagonist, consumed less ethanol (Hendrickson 2009)
and do not acquire a place preference when administered ethanol (Bhutada et al 2012).
nAChRs specifically within the VTA are also implicated in ethanol’s mechanism of action.
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Intra-VTA infusions of MEC reduced ethanol-induced DA release into the NAc (Blomqvist
et al 1996).
More specifically, α4* and α6* nAChRs play an important role in the rewarding properties
of ethanol. α4 nAChR subunits are necessary for ethanol to condition a place preference
in mice (Liu et al 2013a). α6* nAChR activity, specifically within the VTA, is necessary for
both ethanol consumption and reinforcement (Larsson et al 2004) (Lof et al 2007).
Furthermore, enhanced α6* and α4* nAChR activity increases ethanol reward-like
behavior (Liu et al 2013a, Powers et al 2013).
These data indicate that ethanol can modulate nAChRs and nAChRs within the VTA
contribute to the rewarding properties of ethanol. Future studies need to be conducted
to better understand the mechanism of action.
1.10 Effects of Combined Nicotine and Ethanol Administration
Studies utilizing simultaneous nicotine and ethanol co-exposure indicate that the two
drugs have synergistic or additive properties. Results from VTA-containing brain slices
demonstrate ethanol and nicotine have synergistic effects on action potential firing. A
subthreshold concentration of nicotine co-applied with ethanol was able to increase the
firing rate of VTA DA neurons when perfused over brain slices. (Clark & Little 2004).
Similarly, in acute brain slices, ethanol can potentiate ACh-induced increases in the firing
rate of VTA DA neurons, which requires both α4 and α6 nAChR subunits. (Liu et al 2013a,
Liu et al 2013b). Results in vivo show similar trends. In microdialysis experiments in awake
rats, subthreshold intraperitoneal ethanol injections paired with subthreshold intra-VTA
nicotine injections resulted in increased DA release in the NAc (Tizabi et al 2002).
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1.11 Ethanol-Mediated Changes in Synaptic Plasticity
Early work done in vitro provided evidence that glutamatergic signaling may be altered
by ethanol. AMPAR and NMDAR subunit levels were increased in rat primary neuronal
cultures exposed to ethanol (Chandler et al 1999). While not as widely studied as nicotine
or other drugs of abuse, a single ethanol exposure also increases AMPA/NMDA ratios in
VTA DA neurons (Heikkinen et al 2009, Saal et al 2003). Additionally, AMPA/NMDA ratios
are increased after voluntary ethanol self-administration (Stuber et al 2008). To our
knowledge, the role of nAChRs in ethanol-mediated increases in AMPA/NMDA ratios has
not been previously studied.
1.12 Objectives
The overarching goal of these studies is to better understand the role of 6* nAChRs in
addiction. We began by studying their ability to activate VTA DA neurons, moved onto
their role in glutamatergic synaptic plasticity on VTA DA neurons in response to both
nicotine and ethanol exposure, and finally looked into the contribution of 4 nAChR
subunits to 6* nAChR activity.
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METHODS

Portions of this chapter (pgs 23-38) are reprinted from:
Molecular Pharmacology 2013 Sept; 84(3):393-406, doi: 10.1124/mol.113.087346
with permission of the American Society for Pharmacology and Experimental
Therapeutics. All Rights Reserved.
Neuropharmacology 2015 Apr; 91:13-22, doi:10.1016/j.neuropharm.2014.11.014 and
Neuroscience 2015 Sept 24; 304:161-75, doi: 10.1016/j.neuroscience.2015.07.052
with permission from Elsevier. All Rights Reserved.
2.1

Materials

(-) Nicotine hydrogen tartrate salt was obtained from Glentham Life Sciences (Wiltshire,
United Kingdom). Nicotine doses are reported as freebase. 6-cyano-7-nitroquinoxaline2,3-dione

(CNQX),

D-2-amino-5-phosphonopentanoic

acid

(AP-5),

KN-93,

and

tetrodotoxin (TTX) were purchased from Tocris Biosciences (Ellisville, MO). -Conotoxin
MII (CtxMII) was synthesized as previously described (Azam et al 2010). All other
chemicals without a specified supplier were obtained from Sigma (St. Louis, MO).
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2.2

Mice

All experiments were conducted in accordance with the guidelines for the care and use
of animals provided by the National Institutes of Health Office of Laboratory Animal
Welfare, and protocols were approved by the Institutional Animal Care and Use
Committee at Purdue University. All efforts were made to minimize animal suffering, to
reduce the number of animals used, and to utilize alternatives to in vivo techniques when
available. Mice were kept on a standard 12-hour light/dark cycle at 22°C and given food
and water ad libitum. Mice were weaned and group housed with same sex littermates on
postnatal day 21. Tail biopsies were collected 21–28 days after birth and used to
determine the genotype of the mice via polymerase chain reaction (PCR) analysis as
previously described (Drenan et al 2008a). Male and female α6L9S mice and their nontransgenic (non-Tg) littermates were 8–16 weeks old at the time experiments were
conducted. No differences were noted between results obtained from male versus female
mice, so results were pooled.
α6L9S mice were generated as described (Drenan et al 2008a). Briefly, a mouse bacterial
artificial chromosome (BAC) containing the Chrna6 gene was obtained and an L9′S
mutation was introduced by codon replacement using a BAC recombineering approach.
Mutant BAC DNA was introduced into FVB/N embryos, which were then implanted into
pseudopregnant Swiss-Webster surrogates. The BAC insertion site in the mouse genome
is unknown. Founder animals were isolated and have been continuously back-crossed to
C57BL/6 for >12 generations. Over 90% of the α6L9S strain genome is expected to contain
C57BL/6 alleles, but FVB/N allelic DNA close to the insertion site is likely to remain in place
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in this strain. α6L9S mice are thus transgenic and express mutant (L9′S) and wild-type
(WT) α6 nAChR subunits (Cohen et al 2012). α6* nAChR function is sensitized in these
mice, producing a 10- to 100-fold leftward shift in concentration-response relationships
involving α6* nAChRs, depending on the assay being used (Cohen et al 2012, Drenan et al
2010, Drenan et al 2008a). We previously confirmed that α6* nAChRs in α6L9S mice are
not overexpressed or misexpressed in ectopic brain locations (Drenan et al 2010, Drenan
et al 2008a).
α6L9S mice lacking α4 nAChR subunits were generated as previously described (Drenan
et al 2010). α4 knockout (KO) mice were a generous gift of Dr. Michael Marks (University
of Colorado, Boulder, CO), and were produced by mating mice heterozygous for the α4KO
allele. Briefly, α6L9S mice, in which the mutant allele is maintained in a heterozygous
fashion, were crossed to homozygous α4KO mice to produce mice that are heterozygous
for both the α6L9S allele and the α4KO allele. These mice were subsequently crossed to
homozygous α4KO mice to produce mice heterozygous for the α6L9S allele and
homozygous for the α4KO allele.
α6 green fluorescent protein (GFP) mice were generated as previously described (Mackey
et al 2012). To create α6GFP mice lacking α4 subunits, α4KO mice were crossed to α6GFP
mice, generating α6GFP mice heterozygous for the α4KO allele. These mice were crossed
again to mice homozygous for the α4KO allele, yielding α6GFP mice that were also
homozygous for the α4KO allele.
Chrna4 loxP/loxP mouse embryos were a generous gift from Dr. Stephen Heinemann (Salk
Institute for Biological Studies, La Jolla, CA). They were generated as previously described
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(McGranahan et al 2011). Homologous recombination was used to insert loxP sequences
into intronic regions flanking exon V of the 4 gene. Chrna4 loxP/loxP mice were crossed
with 6L9S mice to generate mice with hypersensitive 6* nAChRs and floxed 4 subunit
genes. 4 subunits were removed from Chrna4 loxP/loxP mice by injecting viral vectors
driving the expression of Cre into the brain region of interest as described below. The
virus also drives the expression of GFP. Therefore, Chrna4 loxP/loxP mice that received
intra-VTA Cre virus injections are referred to as Chrna4 ventral midbrain conditional KO
mice (Chrna4 vMB cKO). Control Chrna4 loxP/loxP were injected with a virus that only
drives the expression of GFP. Not every cell is infected with the virus thus when referring
to data from individual neurons, Cre(+) and Cre(-) is indicated. Cre(+) refers to cells that
are from Chrna4 vMB cKO mice that also express the Cre virus (identified by the presence
of GFP). Cre(-) refers to cells from Chrna4 loxP/loxP mice given control GFP virus
injections.
2.3

Stereotaxic Surgery

Adult mice (at least 8 weeks of age) were anesthetized with a ketamine/xylazine cocktail
(6L9S: 100 mg/kg ketamine, 10 mg/kg xylazine; non-Tg and Chrna4 loxP/loxP:
120 mg/kg ketamine, 16 mg/kg xylazine; intraperitoneal (i.p.) injection). The surgical area
was shaved and cleansed via three applications of alternating iodide ointment and 70%
ethanol. Mice were then placed into a stereotaxic frame (Kopf; Tujunga, CA, USA) and a
small incision was made to expose the skull. The skull was leveled in the coronal and
sagittal planes using the coordinates for the bregma and lambda as landmarks. Bilateral
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holes were drilled in the skull according to adjusted coordinates from the third edition of
the Franklin and Paxinos mouse brain atlas (for VTA: M/L: ±0.5 mm from bregma, A/P:
−3.2 mm from bregma; for NAc: M/L: ±0.6 mm from bregma, A/P: +1.5 mm from bregma).
The A/P coordinate was adjusted for each animal to accommodate individual variations in
size; the distance between the bregma and lambda was measured for each mouse and
divided by the published distance in this species (4.21 mm), and this ratio was then
multiplied by the proper A/P coordinate from the atlas to determine the proper A/P
coordinates for each animal. At this point mice were either implanted with guide
cannulae or given intra-VTA or intra-NAc viral injections.
Guide cannulae 3.0 mm in length (Plastics One; Roanoke, VA, USA) along with a dummy
cannula (also 3.0 mm in length; Plastics One) were slowly lowered into position and
secured using Geristore cement (Den-Mat; Lompoc, CA, USA). Animals remained in the
stereotaxic apparatus until the cement fully dried. Once removed from the stereotaxic
apparatus, a dust cap was screwed onto the dorsal portion of the guide cannula to keep
the dummy cannula in place and to prevent contamination of the guide cannula.
Chrna4 loxP/loxP mice and 6L9S/Chrna4 loxP/loxP were injected with viruses that drive
the expression of Cre recombinase in order to remove 4 nAChR subunits. A syringe
loaded with the virus was slowly lowered to D/V coordinates of -4.5 mm from bregma for
intra-VTA injections or -4.4 mm from bregma for intra-NAc injections. For the AAV-GFP
and AAV-GFP-Cre viruses (AAV2.CMV.PI.eGFP.WPRE.bGH and AAV2.CMV.HI.eGFPCre.WPRE.SV40 purchased from Penn Vector Core), 250 nL of virus was infused at a rate
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of 50 nL/min. The injection needle was left in place for 5 minutes after the infusion ended
before slowly retracting the needle out of the brain. For the HSV-YFP and HSV-YFP-Cre
retrograde viruses (hEF1-EYFP and hEF1-EYFP-IRES-cre purchased from the MIT
McGovern Institute Viral Gene Transfer Core), 500 nL of virus was infused at a rate of 50
nL/min. The injected needle was left in place for 10 minutes after the infusion ended
before slowly retracting the needle out of the brain. Sutures were used to close the
incision.
Following surgery, mice were given ketoprofen (5 mg/kg, subcutaneous) and allowed to
recover on a heating pad under close observation until ambulatory. Mice were singly
housed following surgery. Mice implanted with guide cannulae were allowed to recover
for at least 5 days prior to infusions. Mice given viral injections were given 2 (AAV viruses)
or 3 (HSV viruses) weeks to recover and for the virus to reach peak expression.
2.4

in vivo Drug Administration

Prior to receiving i.p. injections, mice were gently handled once a day for three days to
habituate them to handling. The next day, mice were scruffed and given a mock injection.
One day prior to the experiment, mice were scruffed and given a saline injection (i.p.). On
the experimental day, mice were given an i.p. injection of vehicle (0.9% saline), nicotine,
or ethanol. Nicotine was administered at a dose of 0.03 mg/kg or 0.17 mg/kg. Ethanol was
administered at a dose of either 0.5 or 2.0 g/kg. Immediately following the injection, mice
were placed in a novel conditioning chamber for 15 minutes (nicotine) or 5 minutes
(ethanol) before they were returned to their home cage. One hour after the injection mice
were euthanized for brain slice preparation.
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A subset of 6L9S mice received intra-VTA infusions of CtxMII (10 pmol) or vehicle
(sterile saline) immediately prior to nicotine (0.03 mg/kg, i.p.) injections. Infusions were
carried out using a dual syringe pump connected to internal cannulae (extending 1.5 mm
beyond guide cannulae; Plastics One) via two identical Hamilton syringes and PE50 tubing
(Plastics One). Mice were anesthetized using isoflurane (5% for initiation of anesthesia;
1.8% for maintenance). While maintained on isoflurane anesthesia, the dust cap and
dummy cannula were removed and the internal cannula was fully inserted into the guide
cannula. Drugs were infused at a rate of 0.1 μL/min for 5 minutes for a total volume of
0.5 μL. The internal cannula was left in place for an additional 5 minutes to prevent
backflow into the guide cannula. Following the infusion, the internal cannula was
removed and the dummy cannula and dust cap were replaced. The animal was
immediately removed from the isoflurane and allowed to recover (approximately 10
minutes) in the home cage.
2.5

Brain Slice Preparation for Electrophysiology

Mice were anesthetized with sodium pentobarbital (100 mg/kg, i.p.) followed by cardiac
perfusion with oxygenated (95% O2/5% CO2), 4°C N-methyl-D-glucamine (NMDG)
recovery solution containing the following: 93 mM NMDG, 2.5 mM KCl, 1.2 mM NaH2PO4,
30 mM NaHCO3, 20 mM HEPES, 25 mM glucose, 5 mM Na+ ascorbate, 2 mM thiourea, 3
mM Na+ pyruvate, 10 mM MgSO4•7H2O, and 0.5 mM CaCl2•2H2O (300–310 mOsm, pH
7.3–7.4). Brains were removed and retained in 4°C NMDG recovery solution for 1 minute.
Coronal slices (200 μm) were cut with a microslicer (DTK-Zero 1; Ted Pella, Redding, CA).

30
Brain slices recovered for 12 minutes at 33°C in oxygenated NMDG recovery solution,
after which they were held until recording in room temperature HEPES holding solution
containing the following: 92 mM NaCl, 2.5 mM KCl, 1.2 mM NaH2PO4, 30 mM NaHCO3, 20
mM HEPES, 25 mM glucose, 5 mM Na+ ascorbate, 2 mM thiourea, 3 mM Na+ pyruvate, 2
mM MgSO4•7H2O, and 2 mM CaCl2•2H2O (300–310 mOsm, pH 7.3–7.4). Coordinates for
recordings in the VTA were approximately −3.5 mm from bregma, 4.0–4.5 mm from the
surface, and 0.5–1.0 mm from the midline. In adult C57 mice, these coordinates
correspond to NAc lateral shell-projecting VTA neurons, which are expected to be
approximately 96% tyrosine hydroxylase (TH)-positive (Lammel et al 2008).
2.6

Patch-Clamp Electrophysiology

A single slice was transferred to a 0.8-ml recording chamber (RC-27L bath with PH-6D
heated platform; Warner Instruments, Hamden, CT), and slices were superfused
throughout the experiment with standard recording artificial cerebrospinal fluid (1.5–2.0
ml/min) containing the following: 124 mM NaCl, 2.5 mM KCl, 1.2 mM NaH 2PO4, 24 mM
NaHCO3, 12.5 mM glucose, 2 mM MgSO4•7H2O, and 2 mM CaCl2•2H2O (300–310 mOsm,
pH 7.3–7.4). Cells were visualized with an upright microscope (FN-1; Nikon Instruments,
Melville, NY) using infrared or visible differential interference contrast optics. Patch
electrodes were constructed from Kwik-Fil borosilicate glass capillary tubes (1B150F-4;
World Precision Instruments, Inc., Sarasota, FL) using a programmable microelectrode
puller (P-97; Sutter Instrument Company, Novato, CA). The electrodes had tip resistances
of 4.5–8.0 MΩ when filled with internal pipette solution (pH adjusted to 7.25 with Tris
base, osmolarity adjusted to 290 mOsm with sucrose). Three internal pipette solutions
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were used. The following solution was used when recording nicotine- or ACh-evoked
currents (bath application or puff-applied), action potential firing, and spontaneous EPSCs:
135 mM K+ gluconate, 5 mM EGTA, 0.5 mM CaCl2, 2 mM MgCl2, 10 mM HEPES, 2 mM
MgATP, and 0.1 mM GTP. The following solution was used when recording AMPA- or
NMDA-evoked currents and AMPA/NMDA ratios: 117 mM CsCH3SO3, 20 mM HEPES, 0.4
mM EGTA, 2.8 mM NaCl, 5 mM tetraethylammonium (TEA)-Cl, 2.5 mM MgATP, and 0.25
mM GTP. When recording AMPA-evoked currents 100 μM spermine was added to this
internal solution so the rectification index could be evaluated. Finally, inhibitory post
synaptic current (IPSC) recordings were done using an internal solution containing (in
mM): 75 K+ gluconate, 65 KCl, 5 EGTA, 10 HEPES, 0.5 CaCl2, 2 MgATP, 0.1 GTP.
Whole-cell recordings were taken at 32°C with an Axopatch 200B amplifier, a 16-bit
Digidata 1440A A/D converter, and pCLAMP 10.3 software (all from Molecular Devices,
Sunnyvale, CA). Data were sampled at 5 kHz and low-pass filtered at 1 kHz. The junction
potential between the patch pipette and the bath solution was nulled immediately prior
to gigaseal formation. Series resistance was uncompensated.
DA neurons in VTA were identified according to previously published methods (Drenan et
al 2008a, Nashmi et al 2007, Wooltorton et al 2003). We avoided recording from neurons
on the slice surface and neurons deep in the slice that were difficult to visualize. Briefly,
DA neurons were identified via several electrophysiological characteristics: 1) broad spike
width (≥2 milliseconds), 2) slow spontaneous firing (<5 Hz), and 3) expression of
hyperpolarization-activated cation current (Ih).
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To examine the function of somatic ligand-gated ion channels, agonists were locally
applied using a Picospritzer III (General Valve, Fairfield, NJ). Atropine (1 μM) was present
in the bath solution when administering ACh to avoid activation of muscarinic receptors.
During AMPA- and NMDA-evoked current recordings, picrotoxin (a GABAA receptor
antagonist; 75 M) and TTX (a selective sodium channel blocker; 0.5 M) were added to
the recording solution to isolate the recorded DA neuron. A drug-filled micropipette,
identical to a typical recording pipette, was mounted onto a single-dimension
piezoelectric translator (PA-100/12; Piezosystem Jena, Inc., Hopedale, MA), which was
fixed to a micromanipulator (Sutter Instrument Company). Between drug applications,
the drug-filled pipette was maintained ≥100 μm from the recorded cell. To apply drugs to
the recorded cell, pClamp software triggered the piezoelectric translator to advance the
drug-filled pipette to a predetermined position adjacent to the recorded cell (20–40 μm
from the cell), drug was applied to the cell using a 250-millisecond pressure (12 psi)
ejection, and the piezoelectric translator subsequently retracted the drug-filled pipette.
This setup allowed for better reproducibility and reduced receptor desensitization
compared with manual control of the drug-filled pipette. The first application to a cell was
typically with the drug-filled tip approximately 40 μm from the cell, and we subsequently
moved the position of the drug-filled pipette closer to the cell to achieve a more rapid
response. Responses to AMPA were deemed acceptable based on two criteria: 1) the
pressure application caused slight to modest cell movement, and 2) the seal parameters
remained stable for multiple responses. Under these conditions, the 10–90% rise time for
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AMPA application was 222 ± 17 milliseconds. Faster rise times and excessive cell
movement were commonly associated with loss of a stable seal. Responses were much
slower (10–90% rise time was 546 ± 75 milliseconds) when the cell did not move during
the application.
AMPA to NMDA ratio recordings were carried out as previously described (Etherton et al
2011, Mao et al 2011), but with minor modifications. Coronal slices were used (as for
AMPA-evoked currents), neurons were chosen as described above, and whole-cell
recordings were established. Picrotoxin (75 μM) was added to the recording solution. A
concentric bipolar stimulating electrode (FHC cat. #CBAPC75) was placed 100–200 μm
lateral to the recorded cell, typically in/around the medial lemniscus in the ipsilateral
hemisphere. Synaptic responses were stimulated (250–750 μA, 40 μsec, 0.1 Hz) such that
evoked EPSCs were ∼50% of maximum amplitude. First, the cell was held at a command
voltage of −70 mV, and an EPSC was evoked. Because there is little to no current through
NMDA receptors at a membrane potential of −70 mV (due to Mg2+ block), the response
at −70 mV, and therefore the time to peak, is likely to be completely mediated by AMPARs.
Five sweeps were recorded at −70 mV, and the average time-to-peak was noted and
subsequently used to measure AMPAR-mediated EPSCs at +40 mV. Next, cells were
depolarized to a command voltage of +40 mV and membrane current was allowed to
stabilize for several minutes prior to evoking EPSCs. EPSCs were again evoked, and 5
sweeps were averaged. The amplitude of the AMPA-mediated component at +40 mV was
estimated to be the membrane current value at the time corresponding to when the
evoked EPSCs peaked when the command voltage was −70 mV. The NMDA component
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was derived by averaging the membrane current value during a 10 millisecond window
that began 40 milliseconds after the time of the peak AMPAR response. Because AMPA
components of evoked EPSCs decay to baseline well before 40 milliseconds, this window
accurately isolates the NMDA-mediated component of the evoked EPSC. AMPA
components at +40 mV and NMDA components at +40 mV were used to derive an
AMPA/NMDA ratio for each cell. This method was shown to yield results congruent with
those obtained using AP-5 to pharmacologically isolate NMDA and AMPA components of
the evoked EPSC in recordings of nicotine-evoked plasticity from VTA DA neurons (Mao
et al 2011). In a subset of cells, we verified our measured AMPA/NMDA ratios by using
AP-5 to pharmacologically isolate NMDA and AMPA components. For all recordings in VTA,
one or two slices per animal were used, and data were obtained from between one and
six cells per slice.
A current injection protocol was used to record action potential firing and measure
changes in excitability of VTA DA neurons in Chrna4 loxP/loxP control slices versus Cre(+)
VTA DA neurons in Chrna4 vMB cKO slices. In current clamp mode, current was injected
from -40 to +80 pA in 20 pA intervals. Each step lasted 2 seconds.
Spontaneous EPSCs and IPSCs were measured while holding the cell at -60 mV in voltage
clamp mode with the internal solution specified above. CNQX (10 M), an AMPA/kainate
receptor antagonist, was added to the recording solution during IPSC recordings to
exclude the possibility of recording EPSCs. At the end of the recording in a subset of cells,
picrotoxin (100 M), a GABAA receptor antagonist, was bath applied to confirm the events
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recorded were GABA receptor mediated IPSCs. Picrotoxin (100 M) was added to the
recording solution during EPSC recordings to exclude the possibility of recording IPSCs. At
the end of the recording in a subset of cells, CNQX (10 M), was bath applied to confirm
the events recorded were AMPAR mediated EPSCs. Instantaneous frequency and
amplitude were analyzed using the threshold search feature of Clampfit. First, the
baseline was adjusted to zero to correct for any baseline drift before starting the
threshold search. The threshold search was set to detect events between two cursors
placed two minutes apart. For IPSCs, CNQX bath application was started immediately
after whole-cell access was established. Therefore the time window was set to start a
minimum of 8 minutes after the start of CNQX bath application.

Negative going

deflections were detected as events by placing the top level marker at zero and the
bottom level marker below the baseline current. Any event crossing the bottom level
marker was detected as an event when the threshold search was ran. At the completion
of the run, the shape of event was manually examined so any noise detected as an event
could be rejected. A results summary sheet was automatically generated by Clampfit. It
included the instantaneous frequency and amplitude of each event. All events per cell
were averaged to give the data points displayed in the figures.
2.7

Single-Cell RT-PCR

These methods for reverse transcription (RT)-PCR were adapted from (Zhao-Shea et al
2011). VTA neurons were studied using the K+ gluconate-based internal solution listed
above but made with DEPC-treated water. After whole-cell recording, the recorded cell
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was aspirated into the pipette, under visual control, with gentle negative pressure. Input
resistance was monitored during aspiration. Successful PCR reactions were typically only
attained when a seal resistance of > 1 GΩ was maintained after aspiration. Cellular
contents were expelled into 75% ethanol, and RNA was precipitated and isolated by
centrifugation at 4°C. cDNA was formed from RNA via reverse transcription (Sensicript
RT, Qiagen) using oligo-dT primers, and a nested PCR strategy was subsequently used to
detect target mRNA species. In round #1 of nested PCR, TH and glyceraldehyde-3phosphate dehydrogenase (GAPDH) cDNA was amplified (1 cycle: 94°C 2 minutes; 20
cycles: 94°C 1 minute, 56°C 1 minute, and 72°C 1.5 minutes; 1 cycle: 72°C 10 minutes)
with

the

following

primers:

TH_F

(CAGTGATGCCAAGGACAAGC),

TH_R2

(GAGAAGGGGCTGGGAACTTT), GAPDH_F2 (AACTTTGGCATTGTGGAAGG), and GAPDH_R2
(CCCTGTTGCTGTAGCCGTAT23).

Subsequently, TH and GAPDH signals were further

amplified (1 cycle: 94°C 2 minutes; 36 cycles: 94°C 1 minute, 56°C 1 minute, 72°C 1.5
minutes; 1 cycle: 72°C 10 minutes) in round #2 with the following primers: TH_F, TH_R1
(CCT GTG GGT GGT ACC CTA TG), GAPDH_F1 (GTG TTC CTA CCC CCA ATG TG), and
GAPDH_R1 (GGT CCT CAG TGT AGC CCA AG).
2.8

Immunohistochemistry and Confocal Microscopy.

Transgenic mice expressing α6* nAChR subunits fused in-frame with GFP (α6GFP
mice; n = 3), along with α6GFP mice homozygous for the α4KO allele, were anesthetized
with sodium pentobarbital (100 mg/kg i.p.) and transcardially perfused with 15 ml of
heparin-containing ice-cold phosphate-buffered saline (PBS) followed by 30 ml ice-cold 4%
paraformaldehyde in PBS. Brains were removed and postfixed overnight at 4°C. Coronal
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sections (50 μm) were cut on a microslicer and collected into PBS. Sections were
permeabilized (20 mM HEPES, pH 7.4, 0.5% Triton X-100, 50 mM NaCl, 3 mM MgCl2, 300
mM sucrose) for 1 hour at 4°C, blocked [0.1% Triton X-100, 5% donkey/horse serum in
Tris-buffered saline (TBS)] for 1 hour at room temperature, and incubated overnight at
4°C in solutions containing primary antibodies (diluted in 0.1% Triton X-100, 5% donkey
serum in TBS). Sections were stained with rabbit anti-GFP primary antibodies (A11122;
Invitrogen, Carlsbad, CA) with a final dilution of 1:500. Sections were washed three times
for 10 minutes each in TBS/Tween 20 (0.1% Triton X-100 in TBS) followed by incubation
at room temperature for 1 hour with goat anti-rabbit Alexa 488 secondary antibodies
(A11008; Invitrogen) diluted in 0.1% Triton X-100, 5% donkey serum in TBS. Sections were
then washed three times in TBS/Tween 20 for 10 minutes each. Sections were stained
with Qnuclear Deep Red Stain (1:1000, Q10363; Invitrogen) in PBS for 20 minutes at room
temperature followed by three 5-minute washes in PBS. All sections were mounted on
slides and coverslipped with Vectashield (Vector Laboratories, Burlingame, CA), and then
imaged with a Nikon A1 laser-scanning confocal microscope system (Nikon Instruments).
Nikon Plan Apo 10X air and 60X oil objectives were used. Alexa 488 was excited with an
argon laser at 488 nm. VTA DA neurons were imaged at 60X, and mean pixel intensity per
cell was measured for >100 cells in both α6GFP and α6GFPα4KO slices.
Slices from Chrna4 vMB cKO mice were treated with the same staining and imaging
procedure with the exception of a modified permeabilization step.

Slices were

alternatively permeabilized with a two minute incubation in PBS-Triton X (0.3% Triton X100 in PBS). Sections were co-stained with sheep anti-TH (1:800) and rabbit anti-GFP
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(1:500). Secondary antibodies used include anti-sheep Alexa 555 and anti-rabbit Alexa
488 with a final dilution factor of 1:500.
2.9

Statistical Analysis.

Statistical analysis was performed with GraphPad Prism 6 software (GraphPad Software,
Inc., La Jolla, CA). Data are reported as the mean ± standard error of the mean (S.E.M.).
To determine whether data sets were normally distributed, all data sets were subjected
to a D’Agostino and Pearson omnibus normality test. Only when all data sets to be
compared passed this normality test (α level = 0.05) were parametric statistical tests used.
For data sets that were either not normally distributed or not large enough for a normality
test, statistical significance (P < 0.05) was assessed with nonparametric tests. A student’s
t-test or a Mann–Whitney test was used for comparisons between two groups. One-way
analysis of variance (ANOVA) or a Kruskal–Wallis (nonparametric one-way analysis of
variance) test followed by a Dunn’s post hoc test was used for comparisons between three
or more groups. Concentration-response curve data were fitted to the Hill equation. Error
bars for plotted EC50 values indicate 95% confidence intervals.
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462* nAChR ACTIVATION ON VTA DA NEURONS IS SUFFICIENT TO
STIMULATE A DEPOLARIZING CONDUCTANCE AND ENHANCE SURFACE AMPA
RECEPTOR FUNCTION

Portions of Sections 3.1 and 3.3-3.10 (pgs 39-41; 44-65) are reprinted from Molecular
Pharmacology 2013 Sept; 84(3):393-406, doi: 10.1124/mol.113.087346 with permission
of the American Society for Pharmacology and Experimental Therapeutics. All Rights
Reserved.
Portions of Sections 3.2, 3.11-3.12 (pgs 43; 66-69) are reprinted from Neuroscience 2015
Sept 24; 304:161-75, doi: 10.1016/j.neuroscience.2015.07.052 with permission from
Elsevier. All Rights Reserved.

3.1

Electrophysiological Identification of VTA DA Neurons

To study VTA DA neurons in adult mice (aged ≥60 days), we prepared coronal slices and
recorded from VTA cells residing in the lateral aspect of the VTA. Although the VTA is
emerging as a heterogeneous structure (Lammel et al 2011), 96.3% of neurons in this area
test positive for TH expression in adult C57 mice, and these cells exhibit Ih currents
(Lammel et al 2011). VTA neurons in this study typically fired spontaneous (Figure 3.1 A),
wide action potentials (with a width of approximately 2–5 milliseconds; Figure 3.1 B).
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Hyperpolarizing current injections induced “sag” responses in the transmembrane
voltage record (I = 120 pA; Figure 3.1 A), and these cells exhibited inward currents in
response to hyperpolarizing voltage steps (Ih currents; Figure 3.1 C). To provide further
confirmation that these neurons are DAergic, we conducted single-cell RT-PCR reactions
from a subset of recorded neurons. All recorded neurons (n = 5) in lateral VTA with a PCR
signal for GAPDH were also positive for TH mRNA (Figure 3.1 D), and all of these TH(+)
cells exhibited electrophysiological features as shown above (Figure 3.1 A–C). On the basis
of these results and supporting studies in the literature (Lammel et al 2008, Lammel et al
2011, Zhang et al 2010) we proceeded with reasonable confidence that cells with these
characteristics, and in the lateral part of the VTA, were DAergic neurons.
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Figure 3.1 Electrophysiological identification of VTA DA neurons. (A) Whole-cell currentclamp recordings of VTA DA neurons show spontaneous (I = 0 pA), pacemaker firing (1–5
Hz), and “sag” responses in the membrane potential in response to hyperpolarizing (I =
-120 pA) current injections. (B) VTA DA neurons have wide action potentials. The neuron
in (A) indicated with an arrow is shown on an expanded time scale to better view the
action potential width (typically 2–5 milliseconds) seen in the neurons under study. (C) Ih
currents in VTA DA neurons. VTA cells were held at -60 mV in voltage-clamp mode and
membrane current was recorded at baseline and during a voltage step to -120 mV. (D)
Single-cell RT-PCR (done by Dr. Pei-Yu Shih). VTA DA neurons recorded in whole-cell mode
were aspirated into the recording pipette, followed by RT of RNA and subsequent PCR
reactions to detect TH and GAPDH (positive control) expression. Expected band sizes are
as follows: TH = 207 bp and GAPDH = 138 bp (the asterisk indicates a spurious PCR
reaction, possibly generated from external primer pairs). As a negative control, a pipette
was lowered into the slice and mild negative pressure was applied. The pipette was
removed from the slice and assayed with RT-PCR as for a recorded cell.
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3.2

Hypersensitive 6* nAChRs in 6L9S mice

In these experiments we used transgenic 6L9S mice to study the selective activation of
6* nAChRs. In these mice, the leucine at the nine prime position is mutated to a serine
(L9′S) in the second transmembrane domain (TM2) of 6 nAChR subunits. This mutation
results in hypersensitive 6* nAChRs. They are 10- to 100- fold more sensitive than non6* nAChRs (Cohen et al 2012, Drenan et al 2010, Drenan et al 2008a). Therefore, low
concentrations of agonists such as ACh and nicotine can be used to selectively activate
6* nAChRs (Figure 3.2). The leucine residue where the mutation is made is highly
conserved among nAChR subunits and is found in the channel pore. Mutating this leucine
residue to a polar amino acid, such as serine or threonine, has successfully increased the
sensitivity of several different nAChR subunits (Drenan & Lester 2012). It was first
demonstrated with 7 nAChRs in 1991 (Revah et al 1991). Drenan et al first generated
gain-of-function 6L9S transgenic mice in 2008 and carried out studies showing low
doses/concentrations of nicotine act selectively through 6* nAChRs to enhance
locomotor activity, stimulate DA release in striatal synaptosomes, and increase VTA DA
neuron action potential firing rate (Drenan et al 2008a). Here, we use 6L9S mice to test
the hypothesis that 6* nAChR activation in VTA DA neurons is sufficient to elicit
prolonged inward currents and to enhance AMPAR function.
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Figure 3.2 Effect of L9S mutation in 6L9S mice. In 6L9S mice, a Leu to Ser mutation was
introduced at the 9′ position within transmembrane domain 2 of the 6 nAChR subunit
protein. This mutation increases the sensitivity of the population of channels containing
the mutant 6 subunit, allowing ligands such as ACh and nicotine to selectively activate
these channels when low concentrations are used. The theoretical concentration
response curve for most responses involving 6 containing receptors is left-shifted.
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3.3

A Low Concentration of Nicotine is Sufficient to Increase Inward Currents in
VTA DA Neurons

First, we tested the hypothesis that activation of 6* nAChRs is sufficient to elicit inward
currents in VTA DA neurons by recording from VTA DA neurons from adult 6L9S and
non-Tg littermate mice. Whole-cell voltage-clamp recordings from VTA DA neurons were
established using a K+ gluconate-based internal recording solution, and an inhibitor
cocktail containing CNQX (10 M), picrotoxin (75 M), and TTX (0.5 M) was bath-applied
to the cell to eliminate most external influences on membrane potential. We measured
inward currents in response to a 10-minute bath exposure to nicotine. We previously
reported that brief (250 milliseconds) puff-application of 100 nM nicotine elicited small
(approximately 10 pA) inward currents (Drenan et al 2008a). We reasoned that sustained
exposure of VTA DA neurons to 100 nM nicotine could be sufficient to provide prolonged
activation of these cells. Nicotine (100 nM) elicited a significant inward current in 6L9S
VTA DA neurons (mean change in holding current value relative to prenicotine baseline =
-18.0 ± 3.0 pA; Figure 3.3 A, B, and E). Coapplication of CtxMII (100 nM) with nicotine
(100 nM) eliminated these inward currents (mean change in holding current value relative
to prenicotine baseline = –2.7 ± 4.1 pA; Mann–Whitney test, P < 0.05; Figure 3.3 A, B, and
E), suggesting that 6* nAChRs mediate inward currents in response to 100 nM nicotine.
To determine whether responses to 100 nM nicotine were selective for 6* nAChRs in
6L9S slices, 100 nM nicotine was applied to VTA DA neurons from non-Tg littermate
slices. Nicotine (100 nM) only slightly increased inward currents in non-Tg littermate VTA
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DA neurons in this assay (mean change in holding current value relative to prenicotine
baseline = -3.1 ± 0.8 pA; Figure 3.3 C and E), but the same concentration of nicotine
significantly increased inward currents in 6L9S neurons (Mann–Whitney test, P < 0.05;
Figure 3.3 E). CtxMII did not alter this response in non-Tg littermate cells (Figure 3.3 C
and E). As a positive control, we applied 300 nM nicotine to non-Tg VTA DA neurons. This
concentration was sufficient to moderately increase inward currents in these cells (mean
change in holding current value relative to prenicotine baseline = -8.7 ± 2.2 pA; Figure 3.3
D and E), consistent with a previous report (Liu et al 2012). CtxMII did not block these
responses (mean change in holding current value relative to prenicotine baseline = -7.0 ±
1.0 pA; Figure 3.3 D and E), presumably because responses in non-Tg cells are mediated
by both 6* and non-6* (42) nAChRs. Together, these results demonstrate that
selective activation of 6* nAChRs is sufficient to increase inward currents in VTA DA
neurons. Application of 100 nM nicotine to 6L9S slices was used in subsequent
experiments to study the effects of selectively activating 6* nAChRs.
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Figure 3.3 A low concentration of nicotine is sufficient to increase inward currents in VTA
DA neurons. (A) 6L9S or non-Tg control neurons were voltage clamped in whole-cell
mode. Inhibitor cocktail [10 M CNQX, 75 M picrotoxin, 0.5 M TTX] was superfused,
followed by nicotine (100 nM) and then CtxMII (100 nM). A representative experiment
from a 6L9S neuron is shown. Expanded recordings from time points (i), (ii), and (iii) are
shown in B–D. (B–D) Voltage-clamp recording segments from 6L9S (B; 100 nM nicotine),
non-Tg (C; 100 nM nicotine), and non-Tg (D; 300 nM nicotine) VTA DA neurons at (i)
baseline with inhibitor cocktail present, (ii) inhibitor cocktail plus nicotine, and (iii)
inhibitor cocktail/ nicotine plus CtxMII. (E) Summary showing mean holding current
(-pA) change from baseline in response to nicotine (nic), and nicotine plus CtxMII in the
indicated mouse strain (6L9S and non-Tg littermate). *P < 0.05.
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3.4

AMPA-Evoked Current Methodology

The initial exposure of brain cells to smoking-relevant concentrations of nicotine results
in activation of high-sensitivity nAChRs, including those on VTA DA neurons (Calabresi et
al 1989). This exposure to nicotine leads to upregulation of AMPA receptor (AMPAR)
function in these cells (Saal et al 2003), which could support behavioral changes that lead
to nicotine dependence. Because high-sensitivity nAChRs are expressed on VTA DA
neurons, terminals from GABA neurons that synapse onto VTA DA neurons, and other
glutamatergic fibers, it is not known whether activation of nAChRs specifically on VTA DA
neurons can lead to increased AMPAR function. We previously demonstrated that 6*
nAChRs are expressed only in DA neurons in VTA (Mackey et al 2012). We hypothesized
that selective activation of 6* nAChRs in VTA, which should stimulate DAergic neurons
but not other VTA nAChRs (such as those on GABA or glutamatergic terminals)(Drenan et
al 2008a), is sufficient to enhance AMPAR function in these cells.
To measure AMPAR function on the cell surface, we applied AMPA to VTA DA neurons
using a drug-filled pipette (Kobayashi et al 2009, Li et al 2008, Sanchez et al 2010) that
was positioned using a piezoelectric translator. A cell was voltage clamped and a stable
recording was established. The drug-filled pipette remained stationary above/outside the
slice until our recording software delivered an analog signal to the piezoelectric translator,
triggering movement of the pipette to a predetermined position approximately 20–40 m
from the recorded cell. A digital transistor–transistor logic (TTL) pulse (5 V, 250millisecond duration) activated the Picospritzer, resulting in drug delivery to the recorded
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cell. After the TTL pulse, the piezoelectric translator withdrew the drug-filled pipette. This
procedure is summarized in schematic form in Figure 3.4 A. Figure 3.4 B shows a
representative record of the movement of the piezoelectric translator, the TTL pulse, and
a response to 100 M AMPA in a VTA DA neuron.
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Figure 3.4 AMPA-evoked current methodology. (A) A drug-filled pipette is positioned
above/next to the cell being recorded. A piezoelectric translator brings the pipette close
(20–40 m) to the cell, a TTL pulse triggers a pressure ejection that dispenses drug (AMPA)
onto the cell, and the piezoelectric translator withdraws the pipette away from the cell.
(B) Representative recording showing the timing of the TTL pulse, piezo drive movement,
and resulting inward current elicited by application of 100 M AMPA to a VTA DA neuron.
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3.5

Activation of 6* nAChRs is Sufficient to Enhance AMPAR Function on the
Surface of VTA DA Neurons

To test the hypothesis that selective activation of 6* nAChRs is sufficient to enhance
AMPAR function, we prepared coronal slices from 6L9S mice and their non-Tg
littermates. Slices were cut and allowed to recover for 60 minutes, followed by exposure
of the slices to 100 nM nicotine (or a control solution containing no nicotine) for 60
minutes similar to previous studies (Jin et al 2011, Mao et al 2011) (Figure 3.5 A). After a
washout period (≥60 minutes), whole-cell recordings were established in VTA DA neurons
using a Cs-methanesulfonate–based internal solution. AMPA currents were evoked at
holding potentials of -60, 0, and +40 mV. Whereas nicotine (100 nM) exposure did not
alter AMPAR function in non-Tg VTA DA neurons, this treatment was sufficient to robustly
increase AMPA-evoked currents in 6L9S VTA DA neurons (Figure 3.5 B). Mean AMPAevoked current amplitude was not altered by nicotine (100 nM) at -60, 0, or +40 mV in
non-Tg littermates (Figure 3.5 C). In contrast, there was a significant increase in AMPAevoked current amplitude at -60 and +40 mV in 6L9S neurons (-60 mV: control = -173.5
± 29.4 pA, 100 nM nicotine = -358.4 ± 48.5 pA; Mann–Whitney test, P = 0.004) (+40 mV:
control = 82.2 ± 14.3 pA, 100 nM nicotine = 167.1 ± 23.5 pA; Mann–Whitney test, P =
0.0045) (Figure 3.5 D). As a positive control, we incubated non-Tg slices in a higher
concentration of nicotine (500 nM). This treatment led to a significant increase in AMPAevoked currents at a holding potential of -60 mV (control = -184.2 ± 18.3 pA and 500 nM
nicotine = -283.4 ± 35.8 pA; unpaired t test, P = 0.0487) (Figure 3.5 B and C), consistent
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with previously published experiments with VTA DA neurons in slices (Jin et al 2011). We
next sought to determine whether enhanced AMPA-evoked currents in 6L9S slices
treated with nicotine (100 nM) were due to a change in the efficacy versus the potency
of AMPA. First, we constructed an AMPA concentration-response curve to confirm that
changes in AMPA-evoked currents between non-Tg and 6L9S slices were not due to
differences in initial AMPAR sensitivity. Multiple concentrations of AMPA were applied to
6L9S and non-Tg neurons, and the data were fitted to the Hill equation (non-Tg: R2 =
0.9467; 6L9S: R2 = 0.9819). There was no substantial difference in AMPA EC50 in 6L9S
VTA DA neurons compared with non-Tg neurons (EC50 = 174 M for non-Tg, and EC50 =
182 M for 6L9S; Figure 3.5 E). Figure 3.5 E plots these EC50 values along with their
respective 95% confidence intervals. Similarly, we constructed a concentration-response
curve for AMPA-evoked currents in 6L9S slices exposed to nicotine. AMPA at a range of
concentrations was applied to cells in slices exposed to nicotine, and the data were fitted
to the Hill equation (6L9S nicotine: R2 = 0.9942). The EC50 for AMPA-evoked currents in
nicotine-exposed 6L9S slices was shifted to the left compared with 6L9S slices not
exposed to nicotine (EC50 = 37 M; Figure 3.5 F), suggesting an increase in the sensitivity
of AMPARs to AMPA.
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Figure 3.5 Activation of 6* nAChRs is sufficient to enhance AMPAR function on the
surface of VTA DA neurons. (A) Slice treatment procedure. Brain slices from adult 6L9S
and non-Tg littermate mice were cut, recovered for 60 minutes, and incubated for 60
minutes in control recording solution or recording solution plus nicotine (100 nM).
Nicotine was washed out for ≥60 minutes, and whole-cell recordings were established in
VTA DA neurons. (B) AMPA currents were evoked by puff-application of AMPA (100 M)
at holding potentials of -60, 0, and +40 mV. Representative recordings from incubation of
slices in control and nicotine solutions are shown for 6L9S and non-Tg littermate mice.
(C and D) Summary showing mean AMPA-evoked currents ([AMPA] = 100 M) in non-Tg
littermate (C) and 6L9S (D) VTA DA neurons in response to control incubation or nicotine
incubation at the indicated concentration. The numbers of observations were as follows:
non-Tg control (-60 mV, n = 10; 0 mV, n = 7; +40 mV, n = 7); non-Tg 100 nM nicotine (-60
mV, n = 4; 0 mV, n = 4; +40 mV, n = 4), non-Tg 500 nM nicotine (-60 mV, n = 16; 0 mV, n =
12; +40 mV, n = 12), 6L9S control (-60 mV, n = 14; 0 mV, n = 13; +40 mV, n = 13), and
6L9S 100 nM nicotine (-60 mV, n = 11; 0 mV, n = 11; +40 mV, n = 11). (E) AMPA
concentration-response curve in VTA DA neurons. AMPA-evoked currents were measured
in non-Tg and 6L9S neurons. AMPA concentrations and number of observations at each
data point are as follows: non-Tg (1 M, n = 2; 10 M, n = 6; 50 M, n = 5; 100 M, n =
10; 250 M, n = 5; 500 M, n = 14; 1000 M, n = 11), and 6L9S (1 M, n = 2; 10 M, n =
4; 50 M, n = 4; 100 M, n = 14; 250 M, n = 5; 500 M, n = 4; 1000 M, n = 5; 3000 M,
n = 2). Data (mean ± S.E.M.) were fitted to the Hill equation, and the EC 50 (±95%
confidence interval) for each curve is plotted. (F) AMPA concentration-response curve in
6L9S VTA DA neurons. AMPA-evoked currents were measured in 6L9S control slices or
slices incubated in 100 nM nicotine for 60 minutes followed by >60 minutes washout prior
to recording. Control treated6L9S data from (E) are replotted here for reference. AMPA
concentrations and number of observations at each data point for 6L9S slices treated
with nicotine are as follows: 6L9S (1 M, n = 2; 10 M, n = 3; 50 M, n = 2; 100 M, n =
11; 300 M, n = 3; 1000 M, n = 3). Data (mean ± S.E.M.) were fitted to the Hill equation
and the EC50 (± 95% confidence interval) for each curve is plotted. *P < 0.05; **P < 0.01.
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3.6

Time Dependence For Enhancement of AMPA-Evoked Currents in 6L9S VTA
DA Neurons

Next, we studied the time dependence for enhancement of AMPAR function in VTA DA
neurons. As with previous experiments, slices were cut and allowed to recover for 60
minutes. We then compared AMPA-evoked current amplitudes from neurons treated in
four different ways: 1) incubated for 60 minutes in a control solution without nicotine
followed by a washout period of 60–240 minutes prior to recording, 2) incubated for 60
minutes in nicotine (100 nM) followed by a washout period of 60–240 minutes prior to
recording, 3) incubated for 10 minutes in nicotine (100 nM) followed by a washout period
of 60–240 minutes prior to recording, and 4) incubated for 60 minutes in nicotine (100
nM) followed by a washout period of greater than 240 minutes prior to recording (Figure
3.6 A). Exposure of 6L9S slices to 100 nM nicotine for 10 minutes was insufficient to
augment AMPA-evoked currents above control levels (control incubation/washout 60–
240 minutes = -173.5 ± 29.4 pA; 10-minute nicotine incubation/washout 60– 240 minutes
= -213.5 ± 27.9 pA; Figure 3.6 B and C). However, a 60-minute exposure to nicotine was
sufficient to augment AMPA-evoked currents over control (60-minute nicotine
incubation/ washout 60–240 minutes = -351.1 ± 64.9 pA; Kruskal–Wallis test, P < 0.05;
Figure 3.6 B and C). The effect of a 60-minute nicotine exposure was prolonged, as AMPAevoked currents were still enhanced after a washout period of >240 minutes (60-minute
nicotine incubation/washout 60–240 minutes = -411.4 ± 75.5 pA; Kruskal–Wallis test, P <
0.05; Figure 3.6 B and C).
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Figure 3.6 Time dependence for enhancement of AMPA-evoked currents in 6L9S VTA
DA neurons. (A) Slice treatment procedure. Brain slices from 6L9S mice were cut and
recovered for 60 minutes. Slices were then incubated in nicotine (100 nM) for either 10
or 60 minutes, followed in either case by a washout period of ≥60 minutes. Some slices
treated with nicotine for 60 minutes were allowed >240 minutes of washout prior to
recording. (B) Representative AMPA-evoked currents ([AMPA] = 100 M) at +40 and -60
mV in VTA DA neurons in response to treatment detailed in (A). (C) Summary showing
mean ± S.E.M. AMPA-evoked ([AMPA] = 100 M) current in 6L9S VTA DA neurons in
response to the conditions described in (A). *P < 0.05 vs control.
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3.7

Pharmacology of AMPA-Evoked Current Induction in 6L9S VTA DA Neurons

To better understand the mechanism within VTA DA neurons that leads to enhanced
AMPA-evoked currents, we pretreated 6L9S slices for 10 minutes with several
pharmacological agents prior to 60 minutes nicotine (100 nM) exposure, washout, and
subsequent AMPA-evoked current measurements (Figure 3.7 A). Pretreatment of slices
with CtxMII eliminated the enhanced AMPA-evoked currents seen in 6L9S slices
exposed to a control pretreatment prior to nicotine exposure (control = -173.5 ± 29.4 pA,
nicotine = -358.4 ± 48.5 pA, and MII = -221.5 ± 45.8 pA; Kruskal– Wallis test, P < 0.05;
Figure 3.7 B and C). Similarly, blockade of NMDA receptors with AP-5 (10 M) prior to
nicotine treatment eliminated enhanced AMPA-evoked currents (AP-5 = -194.4 ± 32.9 pA;
Figure 3.7 B and C). Previous studies indicate that DA D1/ D5 receptors in VTA may play a
role in altered synaptic plasticity after exposure to drugs of abuse (Gao & Wolf 2007, Mao
et al 2011). Blockade of DA D1/D5 receptors with SCH-23390 (10 M) did not appear to
substantially reduce nicotine-mediated enhancement in AMPA-evoked currents (SCH23390 = -325.0 ± 44.7 pA; Figure 3.7 B and C), but a Kruskal–Wallis test comparing AMPAevoked currents from 6L9S SCH-23390-treated slices and untreated control 6L9S slices
did not reveal a statistical difference. Several previous reports indicate that homomeric
7 nAChRs play a role in nicotine-elicited AMPAR upregulation (Gao et al 2010, Jin et al
2011). However, pretreatment of slices with MLA (10 nM) did not reduce nicotine-elicited
AMPAR upregulation in 6L9S VTA DA neurons (MLA = -497.8 ± 119.8 pA; Kruskal–Wallis
test, P < 0.05; Figure 3.7 B and C). Previous studies indicate that the activity of CaMKII is
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necessary for enhanced AMPAR function after exposure to drugs of abuse (Anderson et
al 2008). Inhibiting CaMKII with KN-93 (cell-permeable inhibitor of CaMKII; 5 M) prior to
nicotine treatment eliminated enhanced AMPA-evoked currents (KN-93 = -209.8 ± 37.8
pA; Figure 3.7 C).
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Figure 3.7 Pharmacology of AMPA-evoked current induction in 6L9S VTA DA neurons.
(A) Slice treatment procedure. 6L9S brain slices were cut and recovered for 60 minutes.
Slices were pretreated for 10 minutes with one of the drugs indicated in B, followed by
cotreatment with the drug plus nicotine (100 nM) for 60 minutes. Slices were washed out
for ≥60 minutes prior to recording. (B) Representative AMPA-evoked currents ([AMPA] =
100 M) at +40 and -60 mV in VTA DA neurons from 6L9S brain slices pre-exposed for
10 minutes to either control recording solution or the following drugs followed by
incubation in 100 nM nicotine for 60 minutes: CtxMII (MII), SCH-23390 (SCH), AP-5, KN93, and MLA. (C) Summary showing mean ± S.E.M. AMPA-evoked currents ([AMPA] = 100
M) in 6L9S VTA DA neurons in response to the conditions described in (A). *P < 0.05;
**P < 0.01 vs control.
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3.8

Enhanced AMPA-Evoked Currents in 6L9S VTA DA Neurons Are Mediated
by 4 nAChR Subunits

Elimination of 4 nAChR subunits via gene knockout has been shown to significantly
reduce 6* nAChR function in synaptosomal DA release experiments (Drenan et al 2010,
Salminen et al 2007, Salminen et al 2004), direct assays of striatal nAChR function in brain
slices (Drenan et al 2010), and in behavioral experiments (Drenan et al 2010). To test the
hypothesis that 4 nAChR subunits are important for 6* nAChR-mediated enhancement
of AMPAR function in VTA DA neurons, we crossed 6L9S mice with 4KO animals to
eliminate 4 nAChR subunits while still retaining gain-of-function 6 subunits (Drenan et
al 2010). Slice treatment in this experiment (Figure 3.8 A) was identical to experiments
reported in Figure 3.5. Whereas nicotine (100 nM) treatment of 6L9S slices leads to
enhanced AMPAR function, identical treatment of slices from 6L9S mice lacking 4
subunits did not increase AMPA-evoked currents (6L9S: control = -173.5 ± 29.4 pA,
nicotine = -358.4 ± 48.5 pA; 6L9S4KO: control = -205.9 ± 23.3 pA, nicotine = -280.3 ±
45.3 pA; Kruskal–Wallis test, P < 0.05 for 6L9S control versus nicotine and P > 0.05 for
6L9S4KO control versus nicotine; Figure 3.8 B and C).
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Figure 3.8 Enhanced AMPA-evoked currents in 6L9S VTA DA neurons are mediated, in
part, by 4 nAChR subunits. (A) Slice treatment procedure. Brain slices from adult 6L9S
and 6L9S4KO littermate mice were cut, recovered for 60 minutes, and incubated for
60 minutes in control recording solution or recording solution plus nicotine (100 nM).
Nicotine was washed out for ≥60 minutes, and whole-cell recordings were established in
VTA DA neurons. (B) Representative AMPA-evoked currents ([AMPA] = 100 M) at +40
and -60 mV in VTA DA neurons from 6L9S and 6L9S4KO brain slices after incubation
in 100 nM nicotine for 60 minutes. (C) Summary showing mean ± S.E.M. AMPA-evoked
currents ([AMPA] = 100 M) in 6L9S and 6L9S4KO VTA DA neurons in response to the
conditions described in A. ***P < 0.001 vs control.
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3.9

6* nAChR Function is Reduced in 4KO Mice

To determine whether these results were due to reduced 6 expression and/or function,
we performed a series of controls using 4KO animals. First, we crossed 4KO mice with
transgenic mice expressing 6 subunits fused with GFP (Figure 3.9 A). This manipulation
results in the production of only (non-4)62* nAChRs (Figure 3.9 B). We used anti-GFP
immunohistochemistry and confocal microscopy, as previously described in these mice
(Mackey et al 2012), to quantify 6* nAChR expression in VTA neurons in 6GFP mice
and 6GFP mice crossed to 4KO mice. We found a small but significant reduction in
6GFP expression in VTA neurons in 6GFP mice lacking 4 subunits compared with
6GFP with intact 4 nAChR subunit expression (4WT = 17,921 ± 698 arbitrary units,
4KO = 14,507 ± 816 arbitrary units; Mann–Whitney test, P = 0.0011; Figure 3.9 C).
Next, we measured 6* nAChR function directly by comparing nicotine- and ACh-evoked
currents in 6L9S mice and 6L9S mice lacking 4 subunits (Figure 3.9 D). In contrast to
ACh-evoked responses in 6L9S VTA DA neurons with intact 4 subunits, responses from
VTA DA neurons in 6L9S slices lacking 4 subunits were smaller (Figure 3.9 E). Inward
current amplitudes after puff-application of both 1 and 100 M ACh were smaller in
6L9S4KO neurons relative to 6L9S neurons (4WT 1 M ACh = -171 ± 30.3 pA, 4KO
1 M ACh = -57.8 ± 21.8 pA, and 4KO 100 M ACh = -77.6 ± 20.2 pA; Figure 3.9 E and F).
Similarly, 6L9S VTA DA neurons lacking 4 subunits were less sensitive to nicotine
compared with 6L9S cells expressing 4 subunits (Figure 3.9 G). Whereas 1 M nicotine
evoked large inward currents in 6L9S VTA DA neurons that express 4 subunits, 30 M
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nicotine was required to elicit inward currents of the same amplitude in 6L9S slices
lacking 4 subunits (4WT 1 M nicotine = -198.4 ± 25.8 pA, 4KO 1 M nicotine = -58.3
± 11.5 pA, and 4KO 30 M nicotine = -189.6 ± 45.4 pA; Figure 3.9 G and H). Together,
these experiments suggest that activation of 462* nAChRs are responsible for
enhanced AMPA-evoked currents in 6L9S VTA DA neurons.
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Figure 3.9 6* nAChR function is reduced in 4KO mice. (A) Schematic of 6GFP
transgenic mice and 6GFP nAChRs. (B) The resulting 6* nAChR that remains after
crossing 6GFP mice to 4KO mice is shown. (C) 6* nAChRs were quantified in 6GFP
and 6GFP4KO VTA DA neurons using anti-GFP immunohistochemistry and confocal
microscopy. Mean per-cell pixel intensity for each genotype is shown. (Done by Hilary
Broderick.) (D) The resulting 6* nAChR that remains after crossing 6L9S mice to 4KO
mice is shown. (E) Representative ACh-evoked currents in 6L9S and 6L9S4KO VTA DA
neurons. VTA DA neurons from both genotypes were patch clamped and ACh was puffapplied (250 milliseconds) at the indicated concentration. (F) Summary showing mean ±
S.E.M. ACh-evoked current in 6L9S and 6L9S4KO VTA DA neurons in response to the
indicated concentration of ACh. (G) Representative nicotine-evoked currents in 6L9S
and 6L9S4KO VTA DA neurons. VTA DA neurons in slices from both genotypes were
patch clamped and nicotine was puff-applied at the indicated concentration. (H)
Summary showing mean ± S.E.M. nicotine-evoked current in 6L9S and 6L9S4KO VTA
DA neurons in response to the indicated concentration of nicotine. **P < 0.01.
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3.10 NMDA-Evoked Currents Are Not Changed by Nicotine in 6L9S VTA DA
Neurons
Next, we tested whether nicotine (100 nM), acting through 6* nAChRs, can increase or
decrease NMDA receptor function on the surface of VTA DA neurons (Ungless et al 2001).
Whole-cell voltage-clamp recordings were established in VTA DA neurons, and NMDA
currents were evoked via puff-application of NMDA at a holding potential of +40 mV.
Incubation of 6L9S and non-Tg slices in nicotine (100 nM) for 60 minutes (Figure 3.10 A)
did not result in changes in NMDA-evoked currents relative to control treatments (control:
non-Tg = 167.8 ± 17.8 pA and 6L9S = 172.8 ± 32.6 pA; nicotine: non-Tg = 185.2 ± 28.5 pA
and 6L9S = 167.3 ± 18.7 pA; Kruskal–Wallis test, P = 0.7893; Figure 3.10 B and C). These
results suggest that although NMDA activation is required for upregulation of AMPAR
function on VTA DA neurons (Figure 3.7), activation of nAChRs does not significantly alter
NMDA function after 60 minutes of exposure to nicotine.
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Figure 3.10 NMDA-evoked currents are not changed by nicotine in 6L9S VTA DA neurons.
(A) Slice treatment procedure. Brain slices from adult 6L9S and non-Tg littermate mice
were cut, recovered for 60 minutes, and incubated for 60 minutes in control recording
solution or recording solution plus nicotine (100 nM). Nicotine was washed out for ≥60
minutes, and whole-cell recordings were established in VTA DA neurons. (B)
Representative NMDA-evoked currents ([NMDA] = 100 M) at +40 mV in VTA DA neurons
from 6L9S and non-Tg littermate brain slices in response to control incubation or
incubation in 100 nM nicotine for 60 minutes. (C) Summary showing mean ± S.E.M.
NMDA-evoked currents ([NMDA] = 100 M) in 6L9S and non-Tg littermate VTA DA
neurons in response to the conditions described in A.
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3.11 Systemic Nicotine Acts Through α6-Containing nAChRs to Enhance AMPA
Receptor Function in VTA DA Neurons

Up to this point we have incubated naïve brain slices in nicotine prior to measuring
AMPAR function. We also wanted to determine whether in vivo activation of α6* nAChRs
is sufficient to support changes in VTA DA neuron synaptic plasticity. We tested the ability
of in vivo nicotine administration to act selectively through α6* nAChRs to enhance
AMPAR function on the surface of these cells. α6L9S and non-Tg control littermate mice
were injected (i.p.) with nicotine or vehicle. After 60 min, mice were sacrificed and brain
slices were prepared (Figure 3.11 A). Again, AMPAR function was measured using local
application of AMPA to the recorded cell. Based on the dose-range found to be sufficient
to stimulate locomotor activity in α6L9S mice (0.02 to 0.05 mg/kg)(Berry et al 2015),
α6L9S and non-Tg mice were injected with 0.03 mg/kg nicotine or vehicle. This dose was
sufficient to enhance AMPA-evoked currents on the surface of VTA DA neurons in α6L9S
mice, but was below threshold in non-Tg mice (α6L9S VEH = -214.2 ± 23.1 pA, α6L9S
nicotine 0.03 mg/kg = -348.6 ± 42.6 pA, P = 0.0293; non-Tg VEH = -203.5 ± 22.2 pA, nonTg nicotine 0.03 mg/kg = -224.0 ± 36.5, P = 0.4848). (Figure 3.11 B and C). A relatively high
dose of nicotine (0.17 mg/kg) was needed to increase the amplitude of AMPA-evoked
currents on the surface of VTA DA neurons from non-Tg mice (non-Tg nicotine 0.17 mg/kg
= -375.7 ± 58.6 pA, P = 0.019)(Figure 3.11 B and C). Thus, a single systemic exposure to
nicotine can act through α6* nAChRs to enhance glutamatergic transmission in VTA DA
neurons.
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Figure 3.11 Systemic nicotine acts through α6-containing nAChRs to enhance AMPA
receptor function in VTA DA neurons. (A) Experimental design. α6L9S mice were injected
(i.p.) with nicotine at the indicated dose. Sixty minutes after nicotine injection, mice were
used to prepare brain slices for patch-clamp recording in VTA DA
neurons. AMPAR currents were elicited by locally puffing AMPA onto the cell body of the
recorded neuron and recording inward currents in voltage clamp mode. (B) A low dose of
nicotine (0.03 mg/kg) is sufficient to enhance AMPAR currents in α6L9S VTA DA neurons.
Representative AMPA-evoked currents from α6L9S and non-Tg mice injected with the
indicated dose of nicotine are shown. (C) Quantification of AMPA-evoked current
responses in VTA DA neurons from α6L9S and non-Tg mice injected with the indicated
dose of nicotine. Mean peak AMPA-evoked currents for each group/treatment are
plotted. Mann–Whitney test: ∗P < 0.05 (non-Tg: VEH n = 4; nicotine (0.03 mg/kg) n = 7;
nicotine (0.17 mg/kg) n = 6; α6L9S: VEH n = 6; nicotine (0.03 mg/kg) n = 8).
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3.12 Inhibition of α6-containing nAChRs in VTA Blocks AMPAR Enhancement by
Systemic Nicotine.
Finally, we tested the hypothesis that systemic, low-dose nicotine administration in α6L9S
mice acts through ventral midbrain α6* nAChRs to enhance AMPA-evoked currents. Prior
to nicotine (0.03 mg/kg; i.p.) challenge, the VTA of α6L9S mice was infused with αCtxMII
(10 pmol) or vehicle (Figure 3.12 A). Brain slices were prepared and AMPA-evoked
currents were measured as before. The nicotine-elicited increase in AMPAR function was
abolished when αCtxMII was infused into the VTA (α6L9S: VEH/VEH = -246.4 ± 42.1 pA,
VEH/nicotine (NIC) = -432.0 ± 40.1 pA, P = 0.0205; MII/NIC = -220.0 ± 31.7 pA,
P = 0.0030)(Figure 3.12 B and C). αCtxMII infusion paired with a vehicle injection did not
show any change over baseline (α6L9S: MII/VEH = -204.9 ± 37.2 pA, P = 0.4738)(Figure
3.12 B and C). Injection sites in the VTA were verified post-hoc (Figure 3.12 D). These data,
along with Figure 3.11, demonstrate that in vivo activation of VTA α6* nAChRs is
sufficient to drive synaptic plasticity changes in VTA DA neurons that are known to be
important for locomotor sensitization and reward behavior.
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Figure 3.12 Inhibition of α6-containing nAChRs in VTA blocks AMPAR enhancement by
systemic nicotine. (A) Experimental design. α6L9S mice were cannulated and vehicle or
αCtxMII (10 pmol) was infused into the VTA. Following VTA infusion, mice were injected
i.p. with saline or nicotine (0.03 mg/kg). Sixty minutes later, brain slices were prepared
for recording. AMPA-evoked currents were elicited by locally puffing AMPA onto the cell
body of the recorded neuron and recording inward cation currents in voltage clamp mode.
(B) Representative AMPA-evoked currents from α6L9S mice injected/infused with the
indicated drugs are shown. (C) Mean peak AMPA-evoked currents for each group shown
in (B) are plotted. Mann–Whitney: ∗P < 0.05, ∗∗P < 0.01. (VEH/VEH: n = 7, MII/VEH: n = 7,
VEH/NIC: n = 8, MII/NIC: n = 8). (D) Cannula location for each mouse in groups indicated
in (B) is shown. (Cannulations and infusions done by Dr. Jennifer Berry.)
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NICOTINE AND ETHANOL COOPERATE TO ENHANCE VTA AMPA
RECEPTOR FUNCTION VIA α6-CONTAINING NICOTINIC RECEPTORS

Portions of this chapter (pgs 70-83) are reprinted from: Neuropharmacology 2015 Apr;
91:13-22, doi:10.1016/j.neuropharm.2014.11.014 with permission from Elsevier. All
Rights Reserved.

4.1

α6* nAChRs Are Involved in Ethanol-Mediated Increases in AMPAR Function
in VTA DA Neurons

α6* nAChRs are crucial for the rewarding properties of ethanol in rodents (Larsson et al
2004, Lof et al 2007, Powers et al 2013). Systemic ethanol exposure is known to enhance
AMPAR function on VTA DA neurons (Saal et al 2003, Stuber et al 2008), but α6* nAChR
involvement in this process has not yet been studied. We began by testing the hypothesis
that exposing slices to drinking-relevant concentrations of ethanol can increase AMPAR
function on VTA DA neurons. VTA-containing brain slices were prepared from adult, drugnaïve mice, and slices were allowed to recover for 60 minutes. Slices were then incubated
in ethanol or a control recording solution without ethanol for 60 minutes. After a washout
period of ≥60 minutes (Figure 4.1 A), stable whole-cell recordings were established in VTA
DA neurons. A second, AMPA-filled, micropipette was programmed to move adjacent to
the recorded cell, pressure-eject (puff) AMPA (100 μM), and be retracted (as in Figure
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3.4). The amplitude of AMPA-evoked currents at a holding potential of −60 mV was
measured to assess AMPAR function.
We found that incubating slices from non-Tg mice in ethanol (20 mM) for 60 minutes
significantly increased AMPAR function in VTA DA neurons over baseline responses from
control

slices

not

exposed

to

ethanol

(control = −187.3 ± 16 pA,

20 mM

ethanol = −319.6 ± 43 pA; ANOVA, P = 0.0034; post hoc test, P < 0.01) (Figure 4.1 B, D and
E). To examine the role of α6* nAChRs, slices were pre-treated with αCtxMII (100 nM) for
10 minutes prior to ethanol incubation. Pretreatment with αCtxMII blocked ethanolevoked increases in AMPAR function in VTA DA neurons (αCtxMII = −216.7 ± 44 pA)
(Figure 4.1 B and E), suggesting an important role for ongoing α6* nAChR activity in this
process. αCtxMII by itself had no effect on AMPA-evoked currents (−182.6 ± 29 pA)
(Figure 4.1 E). In a similar fashion, slices were pre-treated in TTX for 10 minutes prior to
ethanol incubation to examine whether action potential firing during ethanol exposure is
required to evoke an increase in AMPAR function. We found that TTX does not block
ethanol-evoked increases in AMPAR function in VTA DA neurons (TTX = −342.3 ± 44 pA;
P < 0.05) (Figure 4.1 B and E). To corroborate data suggesting that α6* nAChRs play a role
in ethanol-mediated enhancement of AMPAR function, we studied changes in AMPAR
function in slices from α6L9S mice. Because these mice have enhanced α6* nAChR activity
(Drenan et al 2008a), we hypothesized that a lower concentration of ethanol would be
able to evoke increases in AMPAR function compared to non-Tg mice if α6* nAChRs are
playing a role in this process. Baseline AMPAR function is not altered in α6L9S mice. 5 mM
ethanol was insufficient to alter AMPAR function in non-Tg slices (−171.0 ± 24 pA), but
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robustly enhanced AMPAR function in α6L9S slices (control = −180.1 ± 22 pA, 5 mM
ethanol = −416.1 ± 49 pA; ANOVA, P < 0.0001; post hoc test, P < 0.0001) (Figure 4.1 C, D
and F). This enhanced response was also blocked by pretreatment with αCtxMII
(−223.0 ± 26 pA) (Figure 4.1 C and F), whereas αCtxMII alone had no effect
(−192.3 ± 10 pA) (Figure 4.1 F). As in non-Tg mice, TTX blockade of action potential firing
had no effect on ethanol's ability to enhance AMPAR function in α6L9S mice
(TTX = −365.9 ± 56 pA; P < 0.01) (Figure 4.1 C and F).
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Figure 4.1 α6* nAChRs are involved in ethanol-mediated increases in AMPAR function in
VTA DA neurons. (A) Schematic illustrating ethanol (EtOH) exposure after cutting brain
slices containing the VTA. After a 60 minute recovery period, brain slices were incubated
in a control holding solution or an ethanol-containing holding solution for 60 minutes.
Slices were transferred out of ethanol for a ≥60 minute washout period before initiating
whole-cell recordings from VTA DA neurons. An additional group of brain slices were
incubated in an inhibitor (inh), either 100 nM αCtxMII or 0.5 μM TTX, for 10 minutes
before starting the 60 minute ethanol incubation. (B and C) Representative AMPA-evoked
current traces from VTA DA neurons in (B) non-Tg and (C) α6L9S brain slices incubated in
control recording solution or ethanol. AMPA (100 μM) was puff-applied while holding VTA
DA neurons at −60 mV. Scale 100 pA, 5 sec. (D) Summary of AMPA-evoked responses
(mean ± SEM) from VTA DA neurons at a holding potential of −60 mV in α6L9S mice and
their non-Tg littermates. Dotted line indicates average amplitude of baseline AMPAevoked responses. (E and F) Summary of AMPA-evoked current amplitudes (mean ± SEM)
in VTA DA neurons in (E) non-Tg and (F) α6L9S brain slices. *P < 0.05; **P < 0.01;
****P < 0.0001 (one-way ANOVA, Dunnett post-hoc test comparing drug concentration
to no-drug control).
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4.2

α6* nAChRs Mediate Enhanced AMPAR Function After in vivo Ethanol
Administration

Enhanced α6* nAChR activity lowered the concentration of ethanol that is sufficient to
enhance AMPAR function using a slice incubation procedure (Figure 4.1 C, D and F). To
determine whether the same trend occurred after in vivo exposure to ethanol, mice were
administered i.p. injections of ethanol. 60 min after this injection, mice were sacrificed
and VTA brain slices were prepared. To minimize the possible effect of handling-induced
stress, mice were handled once a day for three days, given a mock injection, and given a
saline injection on the day immediately prior to the experiment (Figure 4.2 A). As in the
previous experiment, AMPA was puff-applied onto a VTA DA neuron while recording
inward currents evoked at a holding potential of −60 mV. Relative to a vehicle (saline)
injection, ethanol (2.0 g/kg) significantly increased AMPAR function in VTA DA neurons
in non-Tg

slices

(vehicle: −206.5 ± 24 pA,

2.0 g/kg

ethanol: −365.2 ± 34 pA;

ANOVA, P = 0.0004, post hoc test, P < 0.001) (Figure 4.2 B and D). A dose of 0.5 g/kg
ethanol was insufficient to enhance AMPAR function in VTA DA neurons in non-Tg mice
(−221.4 ± 17 pA) but did enhance AMPAR function in α6L9S mice (vehicle: −197.5 ± 23 pA,
0.5 g/kg ethanol: −395.1 ± 46 pA; unpaired t test, P = 0.0072) (Figure 4.2 B–D). Together,
these slice incubation and in vivo exposure experiments strongly indicate a role for α6*
nAChRs in ethanol-mediated enhancement of AMPAR function in VTA.
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Figure 4.2 α6* nAChRs mediate enhanced AMPAR function after in vivo ethanol
administration. (A) Schematic of experimental procedure. Prior to ethanol injection, mice
were habituated to handling by being handled once a day for three days, given a mock
injection, and given a saline injection. Mice were given an ethanol or control saline
injection 60 minutes prior to cutting brain slices containing the VTA. (B and C)
Representative AMPA-evoked current traces from VTA DA neurons in (B) non-Tg and (C)
α6L9S brain slices cut 60 minutes after a mouse was given a control injection or an ethanol
(0.5 g/kg or 2.0 g/kg) injection. AMPA (100 μM) was puff-applied while holding VTA DA
neurons at −60 mV. Scale: 100 pA, 5 sec. (D) Summary of AMPA-evoked current
responses from VTA DA neurons at a holding potential of −60 mV in brain slices from nonTg and α6L9S mice. The mean ± SEM is plotted while the dotted line indicates amplitude
of baseline AMPA-evoked responses. ***P < 0.001 (one-way ANOVA, Dunnett post-hoc
test comparing drug concentration to no-drug control); ##P < 0.01 (student's t-test
comparing control from 0.5 g/kg in α6L9S mice).
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4.3

AMPAR Function is Enhanced by Nicotine Exposure in non-Tg and α6L9S
Mice

Exposure of naïve brain slices to nicotine also enhances AMPAR function in VTA DA
neurons (Jin et al 2011, Mao et al 2011). Although we demonstrated a role for α6* nAChRs
in this process (Figure 3.5), we did not identify the nicotine concentration range over
which this effect takes place. To examine the action of a combined incubation with
nicotine and ethanol (Figure 4.5 and Figure 4.6), we first identified nicotine
concentrations that were sufficient and insufficient to enhance AMPA-evoked currents
on VTA DA neurons. Brain slices cut from drug-naïve mice were incubated in nicotine for
60 minutes and after a ≥60 minute wash-out period, AMPAR function was measured
(Figure 4.3 A). In non-Tg brain slices, 100 nM nicotine was insufficient to increase AMPAR
function, but 500 nM nicotine was sufficient (control = −187.3 ± 16 pA, 100 nM
nicotine = −166.0 ± 14, 500 nM nicotine = −283.4 ± 36 pA; ANOVA, P = 0.0288; post
hoc test, P < 0.05) (Figure 4.3 B). In α6L9S brain slices, nicotine concentrations as low as
10 nM are sufficient to increase AMPAR function (control = −180.1 ± 22 pA, 10 nM
nicotine = −320.1 ± 41 pA; ANOVA, P = 0.0012; post hoc test, P < 0.05) (Figure 4.3 B). The
highest concentration of nicotine tested that was insufficient to enhance AMPAR function
in α6L9S slices is 3 nM (−234.2 ± 36 pA) (Figure 4.3 B).
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Figure 4.3 AMPAR function is enhanced by nicotine exposure in non-Tg and α6L9S mice.
(A) Schematic illustrating slice treatment procedure. Brain slices containing the VTA were
prepared from non-Tg and α6L9S mice and, after a 60 minute recovery period, incubated
in control holding solution or nicotine-containing holding solution for 60 minutes. Wholecell patch clamp recordings were established in VTA DA neurons ≥60 minutes after slices
were removed from nicotine. (B) Summary of AMPA-evoked current responses from VTA
DA neurons at a holding potential of −60 mV in non-Tg and α6L9S brain slices incubated
in nicotine. The mean ± SEM is plotted while the dotted line represents average
amplitude of baseline AMPA-evoked responses. *P < 0.05; ***P < 0.001 (one-way ANOVA,
Dunnett post-hoc test comparing drug concentration to no-drug control).
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4.4

Nicotine and Ethanol Exposure Enhance Excitatory Synaptic Transmission in
non-Tg and α6L9S Slices

Our AMPA-evoked current approach measures AMPAR function from the total pool of
surface-expressed AMPARs, including synaptic and nonsynaptic receptors. Because
AMPARs are preferentially localized to synapses, we measured ethanol- and nicotineelicited changes in AMPA/NMDA ratios in VTA DA neurons using the same conditions we
used for AMPA-evoked currents (Figure 4.4 A). AMPA to NMDA ratios were measured as
described by McGehee and colleagues (Mao et al 2011). As with AMPA-evoked currents,
AMPA/NMDA ratios were significantly enhanced in non-Tg slices following exposure to
either

20 mM

ethanol

or

500 nM

nicotine

(control = 2.47 ± 0.2,

20 mM

ethanol = 3.90 ± 0.1, 500 nM nicotine = 3.41 ± 0.4 pA; ANOVA, P = 0.0007) (Figure 4.4 C).
Lower concentrations of ethanol (5 mM) or nicotine (100 nM) did not increase
AMPA/NMDA ratios (Figure 4.4 C), just as they did not increase AMPA-evoked current
responses (Figure 4.1 and Figure 4.3 B). Next, we measured AMPA/NMDA ratios in VTA
DA neurons from α6L9S slices incubated with either 5 mM ethanol or 100 nM nicotine –
concentrations sufficient to enhance AMPA-evoked currents in these slices. Incubating
α6L9S slices for 60 minutes in either 5 mM ethanol or 100 nM nicotine was indeed
sufficient

to

increase

AMPA/NMDA

ratios

(control = 2.30 ± 0.2,

5 mM

ethanol = 4.13 ± 0.3, 100 nM nicotine = 3.35 ± 0.2; ANOVA, P = 0.0013) (Figure 4.4 D).
These results, together with our AMPA-evoked current data, suggest that α6* nAChR
activity plays an important role mediating enhanced synaptic plasticity following nicotine
and ethanol exposure.
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Figure 4.4 Nicotine and ethanol exposure enhance excitatory synaptic transmission in
non-Tg and α6L9S slices. (A) Schematic illustrating drug (nicotine or ethanol) exposure
after cutting brain slices containing the VTA. After a 60 minute recovery period, brain
slices were incubated in a control holding solution or a solution containing nicotine or
ethanol (concentrations indicated in (C) and (D)) for 60 minutes. Slices were transferred
out of ethanol for a ≥60 minute washout period before initiating whole-cell recordings
from VTA DA neurons. (B) Exemplary synaptic current evoked in a VTA DA neuron,
showing AMPAR- and NMDAR-mediated components. AMPA EPSCs were measured at a
command voltage of +40 mV (red trace) at the time corresponding to the peak of the
AMPA EPSC elicited at a command voltage of −70 mV (blue trace). NMDA EPSCs were
measured at +40 mV by averaging the membrane current during a 10 msec window 40
msec after the AMPA EPSC peak (the latter had decayed to baseline by this time, resulting
in a current due completely to NMDARs). Scale: 40 pA, 10 msec. (C and D) AMPA/NMDA
ratios (mean ± SEM) in non-Tg (C) and α6L9S (D) VTA DA neurons after exposure of slices
to a control solution or to a solution containing the indicated drug. *P < 0.05; **P < 0.01;
***P < 0.001 (one-way ANOVA, Dunnett post-hoc test).
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4.5

Subthreshold Nicotine and Subthreshold Ethanol Combine to Enhance VTA
AMPAR Function in non-Tg Slices

Because both nicotine (Figure 4.3) and ethanol (Figure 4.1) act through α6* nAChRs to
enhance AMPAR function in VTA DA neurons, we hypothesized that α6* nAChRs may also
play a role in the combined action of nicotine + ethanol. To test this hypothesis, we
incubated brain slices in control recording solution containing both nicotine and ethanol
for 60 minutes and recorded AMPA-evoked currents after a 60 minute washout period
(Figure 4.5 A). Whereas 100 nM nicotine or 5 mM ethanol were insufficient to increase
AMPAR function in non-Tg VTA DA neurons when incubated alone, simultaneous coexposure

to

these

concentrations

enhanced

AMPAR

function

(100 nM

nicotine = −166.0 ± 14 pA, 5 mM ethanol = −171.0 ± 24 pA, 100 nM nicotine + 5 mM
ethanol = −374.3 ± 69 pA; ANOVA, P = 0.0080) (Figure 4.5 B and C). To determine whether
α6* nAChRs play a role in this response, slices were pre-incubated in αCtxMII (100 nM)
for 10 minutes before adding nicotine and ethanol. αCtxMII blocked the combined action
of nicotine + ethanol (−254.8 ± 39 pA) (Figure 4.5 B and C). Varenicline, a partial agonist
at α4β2* and α6β2* nAChRs (Grady et al 2010), is currently used as a smoking cessation
drug. To determine whether varenicline interferes with the combined action of
nicotine + ethanol, slices were pre-incubated in varenicline for 10 minutes followed by
continuous co-incubation of slices in varenicline (1 μM), nicotine (100 nM), and ethanol
(5 mM). Like αCtxMII, varenicline blocked increases in AMPAR function mediated by
nicotine + ethanol co-exposure (−227.8 ± 41 pA) (Figure 5.5 B and C). Varenicline by itself
had no effect on AMPAR function in non-Tg cells (−204.3 ± 25 pA) (Figure 5.5 C).
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Figure 4.5 Subthreshold nicotine and subthreshold ethanol, when combined, enhance
VTA AMPAR function in non-Tg slices. (A) Schematic of slice treatment procedure.
60 minutes after preparing brain slices containing the VTA from non-Tg mice, slices were
incubated in holding solution containing both nicotine (100 nM) and ethanol (5 mM) for
60 minutes. AMPA-evoked currents were elicited and recorded after a ≥60 minute washout period. In some experiments, slices were pre-incubated in either αCtxMII (100 nM) or
varenicline (VAR; 1 μM) for 10 minutes before adding nicotine + ethanol for 60 min.
Varenicline (1 μM, 70 minutes) alone was also tested, as shown in (C). (B) Representative
AMPA-evoked currents from non-Tg VTA DA neurons. Slices were treated for 60 minutes
with nicotine/ethanol in one of the following ways: 1) 5 mM EtOH only, 2) 100 nM
nicotine only, 3) 5 mM EtOH plus 100 nM nicotine. AMPA (100 μM) was puff-applied
while holding VTA DA neurons at −60 mV. Scale: 100 pA, 5 sec. (C) Summary of AMPAevoked current amplitudes (mean ± SEM) in VTA DA neurons in non-Tg brain slices.
*P < 0.05; **P < 0.01; (one-way ANOVA, Dunnett post-hoc test comparing the 5 mM EtOH
group or the 100 nM nicotine group to the EtOH plus nicotine group).
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4.6

Subthreshold Nicotine and Subthreshold Ethanol Combine to Enhance VTA
AMPAR Function in α6L9S Slices

To further test the idea that α6* nAChRs play a role in AMPAR enhancement following
nicotine + ethanol co-exposure, we performed an analogous set of experiments with
α6L9S VTA slices (Figure 4.6 A). We previously determined that 3 nM nicotine (Figure 4.3
B) and 200 μM ethanol (Figure 4.1 D) were each insufficient to enhance AMPAR function
in α6L9S slices when administered alone. However, when co-administered to α6L9S slices,
3 nM

nicotine

and

200 μM

ethanol

enhanced

AMPAR

function

(200 μM

ethanol = −217.8 ± 49 pA, 3 nM nicotine = −234.2 ± 36 pA, 200 μM ethanol + 3 nM
nicotine = −442.1 ± 72 pA; ANOVA, P = 0.0065) (Figure 4.6 B and C). As with non-Tg slices,
pre-treatment with either αCtxMII or varenicline blocked the enhancement in AMPAR
function

seen

following

nicotine + ethanol

co-exposure

(MII: −248.0 ± 25 pA,

varenicline: −252.0 ± 35 pA) (Figure 4.6 B and C). As in non-Tg slices, varenicline alone did
not alter AMPAR function in α6L9S slices (−246.5 ± 28 pA) (Figure 4.6 C).
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Figure 4.6 Subthreshold nicotine and subthreshold ethanol, when combined, enhance
VTA AMPAR function in α6L9S slices. (A) Schematic of slice treatment procedure.
60 minutes after preparing brain slices containing the VTA from α6L9S mice, slices were
incubated in holding solution containing both nicotine (3 nM) and ethanol (200 μM) for
60 minutes. AMPA-evoked currents were elicited and recorded after a ≥60 minute washout period. In some experiments, slices were pre-incubated in either αCtxMII (100 nM) or
varenicline (1 μM) for 10 minutes before adding nicotine + ethanol for 60 minutes.
Varenicline (1 μM, 70 minutes) alone was also tested, as shown in (C). (B) Representative
AMPA-evoked currents from α6L9S VTA DA neurons. Slices were treated for 60 minutes
with nicotine/ethanol in one of the following ways: 1) 200 μM EtOH only, 2) 3 nM nicotine
only, 3) 200 μM EtOH plus 3 nM nicotine. AMPA (100 μM) was puff-applied while holding
VTA DA neurons at −60 mV. Scale: 100 pA, 5 sec. (C) Summary of AMPA-evoked current
amplitudes (mean ± SEM) in VTA DA neurons in α6L9S brain slices. **P < 0.01; (one-way
ANOVA, Dunnett post-hoc test comparing the 200 μM EtOH group or the 3 nM nicotine
group to the EtOH plus nicotine group).
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REMOVAL OF 4-CONTAINING nAChRs FROM THE VENTRAL MIDBRAIN
ALTERS CIRCUITRY WITHIN THE VTA

5.1

Chrna4 vMB cKO Mouse Model

Removal of 4* nAChRs from the VTA leaves (non-4)62* nAChRs as the primary high
sensitivity nAChR subtype (Salminen et al 2007). Therefore, to study the role 6* nAChRs
and 4* nAChRs in an additional model to the 6L9S transgenic mouse model, we utilized
a ventral midbrain 4 conditional KO mouse model (Chrna4 vMB cKO mice). Using mice
that have the 4 nAChR subunit gene flanked by loxP sites (Chrna4 loxP/loxP mice), we
removed 4 nAChR subunits from specific brain regions of adult mice by injecting viral
vectors that drive the expression of Cre recombinase (AAV-Cre-GFP). Cre recombinase is
an enzyme that catalyzes the deletion of floxed genes (Kaspar et al 2002, McGranahan et
al 2011) (Figure 5.1 A). Within the VTA, WT mice express heteromeric nAChRs that can
contain 4 nAChR subunits, 6 nAChR subunits, and/or both subunits [(non-6)42*,
(non-4)62*, and/or 462* nAChRs, respectively]. In Chrna4 loxP/loxP mice, after
an injection of AAV-Cre-GFP, only (non-4)62* nAChRs remain (Figure 5.1 B). The viral
vectors used to drive the expression of Cre also drive the expression of GFP so we can
visually identify infected cells by fluorescence. For controls, Chrna4 loxP/loxP mice were
injected with AAV-GFP, a virus driving the expression of GFP but not Cre. We used
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immunohistochemistry and confocal microscopy to verify that there is virus expression in
the VTA after Cre injections. VTA containing-slices were co-stained with anti-GFP to label
the virus and anti-TH to identify DA neurons. We found that the virus was expressed
throughout the VTA. We saw that both TH(+) neurons (indicated by one arrow) and TH(-)
neurons (indicated by two arrows) express the virus (Figure 5.1 C). TH(-) neurons are
presumably GABAergic, as 35% of neurons within the VTA are GABAergic (Nair-Roberts et
al 2008).
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Figure 5.1 Chrna4 vMB cKO mice. (A) Schematic of the 4 nAChR subunit gene before and
after intra-VTA AAV-CRE-GFP injections. Chrna4 loxP/loxP mice contain loxP sites flanking
exon 5 of the gene encoding the 4 nAChR subunit. To remove 4 nAChR subunits, adult
mice were given intra-VTA injections of AAV-CRE-GFP. The resulting Chrna4 vMB cKO
mice have exon 5 deleted from infected cells and therefore disrupted expression of 4*
nAChRs. (B) Heteromeric nAChRs expressed in the vMB normally include (non6)4*nAChRs, (non-4)6* nAChRs, and 46* nAChRs. Following intra-VTA Cre
injections, both (non-6)4* and 46* nAChRs are deleted leaving only (non-4)6*
nAChRs remaining in the VTA. (C) Immunohistochemistry and confocal microscopy images
of the VTA in a Chrna4 vMB cKO brain slice (green: anti-GFP, red: anti-TH). 60X images
showing both a TH(+) and a TH(-) neuron infected by the virus (indicated by one or two
white arrows, respectively).
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5.2

nAChR Function in Chrna4 vMB cKO Mice

To functionally verify the removal of 4 nAChR subunits in Chrna4 vMB cKO mice, we
measured ACh-evoked currents in VTA DA neurons. VTA DA neurons were held at -60 mV
and the response to puff application of ACh was recorded (Figure 5.2 A, top). Cells
infected with Cre virus (labeled Cre (+) from here on) were identified by the presence of
GFP (Figure 5.2 A, bottom). ACh-evoked currents were significantly decreased in Cre (+)
VTA DA neurons in Chrna4 vMB cKO brain slices compared to Cre (-) VTA DA neurons in
Chrna4 loxP/loxP brain slices (Cre (-) = -84.26 ± 5.2 pA, Cre (+) = -28.50 ± 4.1 pA, P <
0.0001)(Figure 5.2 B and C). This reduced sensitivity to ACh demonstrates that injecting
Cre into the VTA of Chrna4 loxP/loxP mice prevents expression of 4* nAChRs. However,
while ACh-evoked currents were attenuated in Cre(+) neurons, they were not eliminated.
To test the hypothesis that the residual current is mediated by (non-4)6* nAChRs, we
measured ACh-evoked currents from Cre(+) VTA DA neurons before and after bath
application of CtxMII. A significant proportion of the remaining current was CtxMIIsensitive (average Cre(+) current in a subpopulation of cells before CtxMII application =
-33.00 ± 4.2 pA, average Cre(+) current after CtxMII = -12.00 ± 2.3 pA, P = 0.0286)(Figure
5.2 D). nAChR removal was also measured in Chrna4 loxP/loxP mice crossed with
hypersensitive 6L9S mice. A low concentration of 1M ACh selectively activates
hypersensitive 6* nAChRs. When 4* nAChRs are removed in Cre(+) VTA DA neurons,
ACh-evoked currents are significantly reduced (Cre (-) = -128.60 ± 14.4 pA, Cre (+) = -13.25
± 3.3 pA, P = 0.0016)(Figure 5.2 E and F). This demonstrates that the majority of ACh-
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evoked currents in VTA DA neurons in slices from Chrna4 loxP/loxP 6L9S mice are
mediated by 46* nAChRs and is consistent with our 4KO6L9S mice results (Figure
3.9).

89

Figure 5.2 nAChR function in Chrna4 vMB cKO mice. (A) Schematic of experimental
approach. VTA DA neurons were voltage clamped at -60 mV during puff application of
ACh. VTA DA neurons expressing Cre (Cre +) were identified by the presence of GFP. (B)
Representative ACh (1 mM)-evoked currents in Cre (-) and Cre (+) VTA DA neurons. Scale:
25 pA, 1 sec. (C) Quantification (average ± S.E.M.) of ACh-evoked current amplitude in Cre
(-) and Cre (+) VTA DA neurons ****P < 0.0001, student’s t-test. (D) Summary of the
reduction in ACh (1 mM)-evoked currents following MII (100 nM) bath application for 4
Cre (+) VTA DA neurons. (E) Representative ACh (1 M)-evoked currents in Cre (-) and Cre
(+) VTA DA neurons in slices from Chrna4loxP/loxP α6L9S and Chrna4 vMB cKO α6L9S
mice. Scale: 25 pA, 1 sec. (F) Quantification (average ± S.E.M.) of ACh-evoked current
amplitude in Cre (-) and Cre (+) VTA DA neurons, **P < 0.01, Mann-Whitney test.
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5.3

Removal of 4 nAChR Subunits Enhances Excitability of VTA DA Neurons

To study the excitability of VTA DA neurons in Chrna4 loxP/loxP and Chrna4 vMB cKO mice,
we injected increasing amounts of current into the cell. Current injection steps lasting 2
seconds were delivered in 20 pA intervals from 0 to +80 pA (Figure 5.3 A). As expected,
the firing rate of VTA DA neurons in control Chrna4 loxP/loxP brain slices steadily
increased with each subsequent current step (Figure 5.3 A and B, gray circles). In 4KO
mice, nicotine does not increase the firing rate, as it does in WT mice (Liu et al 2012).
However, when we give depolarizing current injection steps, action potential firing still
increases in Cre(+) VTA DA neurons in Chrna4 vMB cKO slices (Figure 5.3 A and B, red
circles). In fact, the firing rate is significantly higher in Cre (+) VTA DA neurons compared
to Cre(-) VTA DA neurons at +60 and +80 pA (+60 pA: Cre(-) = 12.30 ± 1.4 Hz, Cre (+) =
20.15 ± 3.8 Hz, P = 0.0350; +80 pA: Cre(-) = 13.35 ± 1.6 Hz, Cre (+) = 22.83 ± 4.8 Hz, P =
0.0435 (Figure 5.3 B). A similar trend towards enhanced excitability in Cre(+) VTA DA
neurons is observed when analyzing the first interspike interval (Figure 5.3 C) with
significant differences occurring at the lowest current injection step of +20 pA. Cre(-) and
Cre(+) VTA DA neurons have a similar baseline action potential firing rate (Figure 5.3 B,
insert) and there is no difference in either the resting membrane potential (Figure 5.3 D)
or the input resistance (Figure 5.3 E).
A study using optogenetics to activate VTA GABA neurons found that stimulation
decreased the excitability of VTA DA neurons (van Zessen et al 2012). Based on this result,
if removal of 4* nAChRs inhibits GABAergic neurons, then we would expect to see the
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increases in VTA DA neuron excitability that we do in Chrna4 vMB cKO mice. Therefore,
we next looked at GABAergic signaling in the VTA of Chrna4 vMB cKO mice.
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Figure 5.3 Removal of 4 nAChR subunits enhances excitability of VTA DA neurons. (A)
Representative action potential firing in a Cre (-) VTA DA neuron from a Chrna4 loxP/loxP
mouse and a Cre(+) VTA DA neuron from a Chrna4 vMB cKO mouse. Current was injected
at each of the indicated values in 2 second steps. (B) Comparison of Cre(-) and Cre(+) VTA
DA neuron firing rate during each current injection step (Cre(-) = gray circles, Cre(+) = red
circles). *P < 0.05 (C) Comparison of the first interspike interval (ISI) for Cre(-) and Cre(+)
VTA DA neurons for each current injection step. *P < 0.05 (D) Resting membrane potential
(RPM) of Cre(-) and Cre(+) VTA DA neurons. (E) Input resistance (Rin) of Cre (-) and Cre(+)
VTA DA neurons.
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5.4

4 nAChR Subunit Removal Decreases the Instantaneous Frequency of IPSCs

We next sought to study the mechanism behind the enhanced excitability we see when
4 nAChR subunits are removed from the VTA. The VTA is comprised of around 35%
GABAergic neurons that send local collaterals to inhibit DA neurons in the VTA as well as
project to forebrain sites such as the NAc (Nair-Roberts et al 2008, Van Bockstaele & Pickel
1995). 4* nAChRs are not only located on DA neurons in the VTA, but also on GABAergic
neurons (Klink et al 2001). In Chrna4 loxP/loxP mice, the 4 gene is floxed in all cell types.
Therefore, when Cre is injected into the VTA, the 4 subunit is removed from both
DAergic and GABAergic neurons (Figure 5.1 C). We hypothesize that removal of 4*
nAChRs from GABA interneurons results in reduced ACh-mediated GABA release and
subsequently reduced inhibition of VTA DA neurons. We measured changes in GABAergic
inhibition by recording spontaneous IPSCs in VTA DA neurons of Chrna4 loxP/loxP and
Chrna4 vMB cKO mice (Figure 5.4 A).

IPSC instantaneous frequency is significantly

reduced in Chrna4 vMB cKO mice compared to Chrna4 loxP/loxP mice (lox/lox = 12.01 ±
3.0 Hz, vMB cKO = 2.22 ± 1.2 Hz, P = 0.0047)(Figure 5.4 B, C, an F). We verified that the
currents recorded were GABAergic by showing they can be blocked by bath application
of picrotoxin (Figure 5.4 D). The majority of IPSCs were also blocked by TTX suggesting
that action potential firing, and presumably GABAergic activity, in the VTA is necessary
for a large portion of the IPSCs recorded (Figure 5.4 E). The amplitude of IPSCs was not
altered by the removal of 4 nAChR subunits in Chrna4 vMB cKO mice compared to
Chrna4 loxP/loxP mice (lox/lox = 13.79 ± 2.1 pA, vMB cKO = 10.65 ± 2.0 pA, P =
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0.3337)(Figure 5.4 B, C, and G). This indicates that when 4 nAChR subunits are removed
from the VTA of adult mice, GABAergic inhibition of VTA DA neurons is decreased via a
presynaptic mechanism.
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Figure 5.4 4 nAChR Subunit Removal Decreases the Instantaneous Frequency of IPSCs.
(A) Schematic illustrating experimental approach. VTA DA neurons were voltage clamped
and -60 mV and spontaneous IPSCs were recorded in the presence of CNQX (10 M). (B)
A representative trace of spontaneous IPSCs in a VTA DA neuron in a slice from a Chrna4
loxP/loxP mouse. Scale: 5 pA, 200 msec. (C) A representative trace of spontaneous IPSCs
in a VTA DA neuron in a slice from a Chrna4 vMB cKO mouse. Scale: 5 pA, 200 msec. (D)
Representative trace showing the lack of IPSCs after picrotoxin (100 M) was bath applied
to the slice. Scale: 5 pA, 200 msec. (E) Representative trace showing a reduction in IPSCs
after TTX (0.5 M) was bath applied to the slice. Scale: 5 pA, 200 msec. (F) Summary
(average ± S.E.M.) of IPSC instantaneous frequency. **P < 0.01, Mann-Whitney test. (G)
Summary (average ± S.E.M.) of IPSC amplitude.
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5.5

EPSCs are not altered by removal of 4 nAChR subunits from the VTA

To detect if the enhanced excitability of VTA DA neurons is a direct result of increased
glutamatergic signaling within the VTA, we measured spontaneous EPSCs (Figure 5.5 A).
We found no difference in the instantaneous frequency of spontaneous EPSCs in VTA DA
neurons from Chrna4 vMB cKO mice compared to Chrna4 loxP/loxP mice (lox/lox = 18.20
± 3.3 Hz, vMB cKO = 16.58 ± 2.6 Hz, P = 0.6990)(Figure 5.5 B, C, and E). There was also no
difference in the amplitude of spontaneous EPSCS in VTA DA neurons from Chrna4 vMB
cKO mice compared to Chrna4 loxP/loxP mice (lox/lox = 6.01 ± 0.6 pA, vMB cKO = 5.16 ±
0.8 pA, P = 0.4212)(Figure 5.5 B, C, and F). Events recorded were confirmed to be
glutamatergic EPSCs by blockade with CNQX (Figure 5.5 D). Therefore, we can reasonably
conclude that enhanced excitability of Cre (+) VTA DA neurons is attributable to decreased
GABAergic signaling and not enhanced glutamatergic signaling within the VTA.
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Figure 5.5 EPSCs are not altered by removal of 4 nAChR subunits from the VTA. (A)
Schematic illustrating experimental approach. VTA DA neurons were voltage clamped and
-60 mV and spontaneous EPSCs were recorded in the presence of picrotoxin (100 M). (B)
Representative trace of spontaneous EPSCs in a VTA DA neuron in a slice from a Chrna4
loxP/loxP mouse. Scale: 5 pA, 200 msec. (C) Representative trace of spontaneous EPSCs
in a VTA DA neuron in a slice from a Chrna4 vMB cKO mouse. Scale: 5 pA, 200 msec. (D)
Representative trace showing the lack of EPSCs after CNQX (10 M) was bath applied to
the slice. Scale: 5 pA, 200 msec. (E) Summary (average ± S.E.M.) of EPSC instantaneous
frequency. (F) Summary (average ± S.E.M.) of EPSC amplitude.
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5.6

Removal of 4 nAChR Subunits from NAc-Projecting VTA Neurons

To confirm that the reduction in IPSC instantaneous frequency is a result of 4 nAChR
subunit removal from neurons within the VTA, we also measured IPSCs after injecting
mice with a retrograde HSV-CRE-YFP virus into the NAc (Figure 5.6 A). Because the
retrograde virus is taken up by terminals in the NAc and transported back to the VTA, 4*
nAChRs are only removed from VTA neurons in the mesolimbic pathway (Figure 5.6 A).
Just as with the intra-VTA AAV-CRE-GFP injections, we again see that both TH(+) and TH(-)
VTA neurons express the virus (Figure 5.6 B). When recording spontaneous IPSCs we
found that IPSC instantaneous frequency is still significantly decreased in VTA DA neurons
in Chrna4 vMB cKO brain slices compared to VTA DA neurons in Chrna4 loxP/loxP control
slices (lox/lox = 10.39 ± 1.4 Hz, NAc to VTA cKO = 4.46 ± 1.0 Hz, P = 0.0031)(Figure 5.6 C,
D, and E) There are no significant change in the spontaneous IPSC amplitude in VTA DA
neurons in Chrna4 vMB cKO brain slices compared to VTA DA neurons in Chrna4 loxP/loxP
control slices (lox/lox = 12.06 ± 2.8 pA, NAc to VTA cKO = 11.82 ± 2.0 pA, P = 0.6241)(Figure
5.6 C, D and F). Therefore, changes in spontaneous IPSC instantaneous frequency are a
result of decreased GABA release from neurons within the VTA and not GABAergic
neurons in other nearby brain regions the AAV virus may have spread to, such as the
GABA-rich rostromedial tegmental nucleus (RMTg) that sends projections to the VTA but
not the NAc (Barrot et al 2012).
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Figure 5.6 Removal of 4 nAChR Subunits from NAc-Projecting VTA Neurons. (A)
Schematic of retrograde viral injection. When retrograde HSV-CRE-YFP viral vectors are
injected into the NAc they are transported to the VTA via terminals of any neurons
projecting from the VTA to the NAc. (B) Immunohistochemistry and confocal microscopy
images of the VTA in a Chrna4 vMB cKO brain slice (green: anti-GFP, red: anti-TH). 60X
images showing both a TH(+) and a TH(-) neuron infected by the virus (indicated by one
or two white arrows, respectively). (C) Representative trace of spontaneous IPSCs in a
VTA DA neuron in a slice from a Chrna4 loxP/loxP mouse. Scale: 5 pA, 200 msec. (D)
Representative trace of spontaneous IPSCs from a VTA DA neuron in a slice from a Chrna4
vMB cKO mouse. Scale: 5 pA, 200 msec. (E) Summary (average ± S.E.M.) of IPSC
instantaneous frequency. **P < 0.01, Mann-Whitney test. (F) Summary (average ± S.E.M.)
of IPSC amplitude.
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5.7

Nicotine-Mediated Enhancement of Excitatory Synaptic Transmission in VTA
DA Neurons Requires 4* nAChRs

In our 4KO6L9S mouse model, incubating brain slices in nicotine did not significantly
enhance AMPAR function on VTA DA neurons (Figure 3.8). Here, we want to see if there
is a similar effect when 4* nAChRs are removed selectively from the VTA of adult mice
and nicotine is administered systemically. Chrna4 loxP/loxP mice were given intra-VTA
injections of AAV-GFP or AAV-Cre-GFP viral vectors followed by a two week recovery and
handling period before they were given a vehicle or nicotine injection (0.17 mg/kg, i.p.).
One hour after the injection, VTA-containing brain slices were prepared for
electrophysiology and AMPA/NMDA ratios were measured (Figure 5.7 A). When 4*
nAChRs are intact, nicotine significantly enhances AMPA/NMDA ratios in VTA DA neurons
(Cre(-)/saline injection: 2.38 ± 0.2 pA, Cre(-)/nicotine injection: 3.85 ± 0.1, P < 0.01)(Figure
5.7 B). However, when 4* nAChRs are removed from VTA DA neurons there are no
significant changes in AMPA/NMDA ratios following a nicotine injection (Cre(+)/saline
injection: 2.20 ± 0.1 pA, Cre(+)/nicotine injection: 2.49 ± 0.2(Figure 5.7 B). This shows that
removal of 4* nAChRs from the VTA of adult mice disrupts the ability of acutely delivered
nicotine to induce changes in synaptic plasticity. Under these conditions, just as in
4KO6L9S mice, activation of (non-4)6* nAChRs is not sufficient to support induction
of plasticity in VTA DA neurons.
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Figure 5.7 Nicotine-mediated enhancement of excitatory synaptic transmission in VTA DA
neurons requires 4* nAChRs. (A) Schematic illustrating experimental procedure. Chrna4
loxP/loxP mice were given intra-VTA AAV-CRE-GFP (or control AAV-GFP) injections at least
two weeks prior to a nicotine (0.17 mg/kg, i.p.) injection. 60 minutes after the nicotine
injection, VTA brain slices were prepared for electrophysiology to measure AMPA/NMDA
ratios. Example evoked synaptic currents recorded from a VTA DA neuron to illustrate
AMPAR- and NMDAR-receptor components. The AMPAR-mediated component was
measured at a command voltage of +40 mV (blue trace) at the time corresponding to the
peak of the AMPA EPSC evoked at a command voltage of -70 mV (red trace). The NMDARmediated component was measured on the +40 mV trace by averaging the membrane
current during a 10 msec window, 40 msec after the AMPA EPSC peak. Scale: 40 pA, 10
msec. (B) Quantification of AMPA/NMDA ratios measured from Cre(-) and Cre(+) VTA DA
neurons following a saline or nicotine (0.17 mg/kg, i.p.) injection. **P < 0.01 (KruskalWallis test, followed by Dunn’s post hoc test)
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5.8

Summary of Proposed Circuitry Changes in the VTA of Chrna4 vMB cKO Mice

Based on the results in this chapter, we propose that the increased excitability observed
in VTA DA neurons of Chrna4 vMB cKO mice when current is injected (Figure 5.3) is a
result of disinhibition. We hypothesize that when 4 nAChR subunits are removed from
the VTA, cholinergic inputs no longer stimulate GABAergic interneurons, resulting in less
GABA release onto VTA DA neurons (Figure 5.8). This reduced inhibition could then in
turn cause enhanced excitability of VTA DA neurons.
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Figure 5.8 Summary of proposed circuitry changes in the VTA of Chrna4 vMB cKO mice.
(A) VTA of control Chrna4 loxP/loxP mice with 4* nAChRs intact. (B) VTA of Chrna4 vMB
cKO mice with 4* nAChRs deleted. Without 4* nAChRs, GABAergic neurons are not
stimulated by cholinergic inputs from the LDTg/PPTg. Therefore, less GABA is released
onto DA neurons. This disinhibition may result in enhanced excitability of VTA DA neurons.
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DISCUSSION

Portions of Sections 6.1-6.4 (pgs 104-112) are reprinted from Molecular Pharmacology
2013 Sept; 84(3):393-406, doi: 10.1124/mol.113.087346 with permission of the American
Society for Pharmacology and Experimental Therapeutics. All Rights Reserved.
Portions of Sections 6.5-6.6 (pgs 112-116) are reprinted from Neuropharmacology 2015
Apr; 91:13-22, doi:10.1016/j.neuropharm.2014.11.014 with permission from Elsevier. All
Rights Reserved.
6.1

Mouse Models

Mice are an ideal model organism for studying nicotine addiction. Mice and humans have
genomes that are roughly 90% identical (Monaco et al 2015) and they share similar brain
reward circuitry (Laviolette & van der Kooy 2004). In addition to WT mice, several
genetically modified mice were used in these studies, including 6L9S transgenic mice,
4KO mice, and Chrna4 loxP/loxP mice. nAChRs containing the 6 subunit have been
difficult to study because, as of yet, they have not been robustly and repeatedly expressed
in vitro in heterologous expression systems without modifications such as chimeric
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subunits or concatamers (Letchworth & Whiteaker 2011). Therefore, native 6* nAChRs
must be studied in vivo or in acute brain slices. Much of the published work on 6 nAChRs
reveals information about the necessity of the receptor through the use of 6KO mice or
pharmacological inhibitors such as CtxMII. These approaches have several drawbacks
including compensatory changes that may have occurred during development in 6KO
mice, and the inability of inhibitors to distinguish between specific receptor subtypes like
(non-4)6* nAChRs versus 46* nAChRs. Our approach using 6L9S mice allows us to
complement these approaches by demonstrating sufficiency versus necessity (Drenan &
Lester 2012). These mice develop normally and express 6 nAChR subunits in the correct
brain regions (Drenan et al 2008a). Although previous work indicates no evidence for
overexpression of 62* nAChRs (Drenan et al., 2010), the TM2 pore-lining mutation
used to sensitize these receptors may alter their pharmacological properties (Labarca et
al 1995, Revah et al 1991). Future studies using restricted expression of 46L9S2*
nAChRs via concatamers (Kuryatov & Lindstrom 2011) will be useful in exploring the latter
possibility, whereas development of 62*-selective ligands will be useful in addressing
the importance of the former possibility.
Crossing 6L9S mice with 4KO mouse models also proved useful in our studies to gain
additional information on the role of 6* nAChRs. When 4* nAChRs are removed, the
primary high sensitivity receptor remaining in the VTA is the (non-4)6* nAChR
(Salminen et al 2007). The contribution of 46* nAChRs can be studied by comparing
results from 6L9S mice to 6L9S mice crossed with 4KO mice as previously done
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(Drenan et al 2010). In addition to the traditional 4KO mouse model, we also used a
conditional 4KO approach (Figure 5.1). Using Chrna4 loxP/loxP mice we have
successfully applied Cre-lox technology to remove 4 nAChR subunits from the VTA of
adult mice (Figure 5.1). By using adult mice we can overcome any possible compensatory
changes that might occur during development. In addition, we can selectively target
certain brain regions to study the contributions of 4 subunits in that brain region instead
of in a global KO mouse. Thus far, our approach does not distinguish between the role of
4* nAChRs on different cell populations within the VTA (Figure 5.1 C). Future studies by
our group will address this.
6.2

VTA DA Neuron Activation by 62* nAChRs

Understanding which nAChR subtypes are necessary and sufficient to mediate nicotine’s
complex action on VTA neurons is a challenge (Drenan and Lester, 2012), and our data
provide new information. We show that nicotine-elicited activation of somatodendritic
62* nAChRs in VTA DA neurons is sufficient to stimulate an inward conductance that
could, under physiologic conditions support prolonged depolarization of these cells
(Figure 3.2). 2* nAChRs are absolutely required for nicotine-induced increases in VTA
DA neuron firing (Maskos et al 2005, Picciotto et al 1998), and Tapper and colleagues
recently reported that activation of 42* nAChRs in VTA DA neurons by smokingrelevant concentrations of nicotine can support depolarization and action potential firing
(Liu et al 2012). These actions were sensitive to a 62* nAChR antagonist, implicating
462* nAChRs. Additionally, the depolarization measured was long-lived but only
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when the 6 nAChR subunit were not inhibited indicating that 462* nAChRs are
desensitization resistant (Liu et al 2012). This report is consistent with our study, which
suggests that selective activation of 62* nAChRs can increase inward currents in VTA
DA neurons (Figure 3.2). Other reports studying the role of VTA 62* nAChRs in nicotine
self-administration (Gotti et al 2010, Pons et al 2008) and DA release (Gotti et al 2010)
support the data we present here. Furthermore, our experiments employing puffapplication of nicotine and ACh in 6L9S, 6L9S4KO, and Chrna4 vMB cKO brain slices
(Figures 3.9 and 5.2) provide evidence that 4 subunits play an important role in 6mediated neuronal activation. In the VTA, 42* nAChRs are found in DAergic neurons
and in GABAergic neurons and/or terminals (Nashmi et al 2007). Nicotine may act through
VTA 42* nAChRs via two mechanisms: 1) direct activation at 42* nAChRs on DA
neurons, and/or 2) desensitization of 42* nAChRs in GABAergic neurons leading to DA
neuron disinhibition (Mansvelder et al 2002, Nashmi et al 2007). Because 6* nAChRs
are restricted to DAergic cells in VTA (Mackey et al 2012), our results suggest that direct
action by nicotine on somatodendritic 6* nAChRs may be sufficient to depolarize these
cells. In the human brain, there may be redundant mechanisms in the VTA that allow
nicotine to activate the mesolimbic DA system.
6.3

Methods of Measuring AMPAR Function

Classically, changes in synaptic plasticity on VTA DA neurons after drug exposure have
been assessed by measuring AMPA/NMDA ratios (Saal et al 2003, Ungless et al 2001).
However, without additional experiments, it is difficult to pinpoint if differences in the
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ratio are due changes in AMPAR function, NMDAR function, or a combination of the two.
Our approach involves direct application of AMPA onto the neuron being recorded (Figure
3.4), similar to previous approaches (Kobayashi et al 2009, Sanchez et al 2010). This allows
us to directly measure the function of AMPARs expressed on the cell surface.
Alternatively, NMDAR function can be measured by locally puff applying NMDA onto the
VTA DA neuron during a whole-cell recording (Figure 3.10). Local puff application of drugs
using a Picospritzer has been successfully employed in studies of other ligand-gated ion
channels as well (Drenan et al 2008a, Eggers & Berger 2004). A fundamental difference
in measuring changes in AMPAR function with the ratio method versus the local drug
application method is the population of AMPARs being activated. When measuring
AMPA/NMDA ratios, an electrode is used to stimulate afferents to release glutamate and
activate AMPARs preferentially located at the synapse. When measuring AMPA-evoked
currents, the entire surface of the cell is exposed to AMPA and therefore the function of
the total population of surface AMPARs, both synaptic and extrasynaptic, is measured. To
identify if there are any discrepancies in the two methods, we also began to study
AMPA/NMDA ratios. We found that with both nicotine and ethanol exposure, there is no
difference in measuring the function of synaptic versus extrasynaptic AMPARs (Figures
3.5, 4.1, and 4.4).
6.4

Nicotine-Induced Changes in AMPAR Function.

Our recordings in isolated brain slices demonstrate that selective activation of 62*
nAChRs is sufficient to enhance the function of AMPARs on VTA DA neurons (Figure 3.5).
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To our knowledge, this study is the first to implicate 62* nAChRs in nicotine-induced
changes in glutamatergic synaptic plasticity on VTA DA neurons. A single exposure to
nicotine or other drugs of abuse enhances AMPAR-mediated EPSCs in VTA DA neurons
(Saal et al 2003) which strongly suggests LTP of excitatory inputs to these cells (Luscher &
Malenka 2011, Mansvelder & McGehee 2000, Ungless et al 2001). Subsequent studies
addressing which nAChR subtypes mediate this effect are not completely consistent. In
slice experiments, McGehee and colleagues report that 2* nAChRs (but not 7 nAChRs)
are necessary for increased AMPAR function in synapses after nicotine exposure (Mao et
al 2011), whereas in studies with animals injected with nicotine prior to slice preparation,
Wu and colleagues suggest that nicotine-elicited increases in AMPAR function can
proceed either through 2* or 7 nAChRs (Gao et al 2010, Jin et al 2011). Our results
using naïve or nicotine-exposed slices from adult non-Tg or 6L9S mice are more
consistent with the former, because we find no necessary role for 7 nAChRs in AMPAR
functional enhancement (Figure 3.7). Our results also demonstrate that the contribution
of 4 nAChR subunits are necessary. Enhanced AMPAR function does not occur in VTA
DA neurons in either 4KO6L9S (Figure 3.8) or Chrna4 vMB cKO (Figure 5.7) brain slices
following nicotine exposure. This indicates that activation of (non-4)6* nAChRs is not
sufficient but rather that activation of 462* is necessary for nicotine-evoked
enhancement of AMPAR function.
Our in vitro finding that selective activation 6* nAChRs is sufficient to enhance AMPAR
function on VTA DA neurons is confirmed by our in vivo results. In 6L9S mice, systemic
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administration of 6-selective doses of nicotine (Figure 3.11 B and C) is sufficient to
enhance AMPAR function on VTA DA neurons. This result was directly ascribed to 6*
nAChRs because CtxMII infusion into the VTA immediately prior to systemic nicotine
administration blocked the enhancement of AMPAR function (Figure 3.12).
In VTA DA neurons, changes in both AMPAR distribution and/or composition are
proposed to occur after exposure to nicotine and other drugs of abuse. Several reports
suggest that drug exposure (including nicotine) leads to signal transduction events that
promote exchange of Ca2+ impermeable AMPARs containing GluR2 subunits for highconductance, Ca2+ permeable AMPARs lacking GluR2 subunits (Bellone & Luscher 2006,
Luscher & Malenka 2011). This GluR2-lacking receptor pool typically displays inward
rectification (Isaac et al 2007, Liu & Zukin 2007), and one study confirms the appearance
of this type of AMPAR after a single exposure to nicotine (Gao et al 2010). Another study
on nicotine exposure to VTA DA neurons, however, demonstrated increases in
AMPA/NMDA ratios but no appearance of an AMPAR pool displaying inward rectification
(Baker et al 2013). We find no appearance of inward rectification in AMPA-evoked
currents (Figure 3.5 B and D), which is more consistent with enhancement in numbers of
GluR2-containing AMPARs rather than production of a significant amount of GluR2lacking AMPARs. However, our data showing an increase in AMPAR sensitivity in response
to 62* activation (Figure 3.5 F) support a number of possible mechanisms, including
increased AMPAR conductance—a hallmark of GluR2-lacking AMPARs. Future
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pharmacological studies in 6L9S and WT slices exposed to nicotine are needed to
characterize AMPAR sensitivity changes.
It is also important to understand what circuit and/or molecular signal transduction
events are necessary and/or sufficient to enhance AMPAR function in VTA DA neurons
after nicotine exposure. At the circuit level, an approach utilizing optogenetics
demonstrated conclusively that in vivo activation of VTA DA neurons was sufficient to
promote AMPAR redistribution (Brown et al 2010). Because 62* nAChRs are selectively
expressed in DA neurons in the VTA (Drenan et al 2008a, Mackey et al 2012), our results
lead us to favor a similar conclusion for nicotine: activation of 62* nAChRs on VTA DA
neurons is sufficient to promote enhanced AMPAR function. Two other molecular events
have been shown to be important for induction of synaptic plasticity in VTA DA neurons:
D1/D5 DA receptor activation (Brown et al 2010, Mao et al 2011, Schilstrom et al 2006),
and NMDA receptor activation (Saal et al 2003, Ungless et al 2001). Although our SCH23390 results are inconclusive, NMDA receptor activation is necessary for 62* nAChRmediated increases in AMPAR function (Figure 3.7 C). Although NMDAR activity is
necessary, the mechanism of enhanced AMPAR function does not require enhanced
NMDAR function (Figure 3.10). While the involvement of kinase activity has not been
extensively studied with regards to nicotine-evoked increases in glutamatergic synaptic
plasticity, CaMKII is required for increased AMPA/NMDA ratios after cocaine exposure
(Anderson et al 2008, Liu et al 2014). Cocaine results in the phosphorylation of S831 on
GluR1 subunits by CaMKII, leading to their increased expression at the synapse (Anderson
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et al 2008, White et al 2013). Our results using KN-93 indicate CaMKII activity is necessary
for 62* nAChR-mediated increases in AMPAR function as well (Figure 3.7 C). Further
experiments probing what target sites CaMKII phosphorylates will help determine if
changes in AMPAR composition or distribution lead to enhanced AMPAR function.
Together with previous studies on nicotine and other drugs of abuse, our data studying
62* nAChRs support the contention that there may be multiple mechanisms in place
that nicotine can use to enhance the responsiveness of VTA DA neurons, ultimately
leading to a heightened behavioral response to nicotine.
6.5

Ethanol-Mediated Enhancement of AMPAR Function

Our results indicate that 6* nAChR activity is important in ethanol-mediated
enhancement of AMPAR function both in vitro by incubating naïve VTA-containing brain
slices in ethanol (Figures 4.1 and 4.4) and in vivo by giving mice ethanol injections (Figure
4.2). We demonstrated 6* nAChR involvement with a genetic approach using selective
6* nAChR activation in 6L9S mice and a pharmacological approach by showing that a
6* nAChR antagonist (CtxMII) blocks ethanol-mediated enhancement of AMPAR
function (Figure 4.1). This suggests that endogenous ACh and ethanol combine at 6*
nAChRs to produce sufficient nAChR activity to initiate signaling events ultimately
resulting in AMPAR functional enhancement. ACh, presumably released from LDTg
and/or PPTg axon terminals, is present in VTA slices and contributes to baseline 6*
nAChR activity in VTA DA neurons (Drenan et al 2008a). Our findings with nicotine in
6L9S4KO mice (Figure 3.8) and previous reports on 46* nAChRs (Drenan et al 2010,
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Liu et al 2012), suggest that 4 nAChR subunits are incorporated into 6* nAChRs that
mediate these effects. Thus, most VTA 6* nAChRs contain 4 and 2 subunits and
462* nAChRs could thus be subject to ethanol's nAChR potentiating properties.
Ethanol is known to alter DA neuron activity and accumbal DA release via indirect, activitydependent mechanisms. For example, ethanol increases ACh release in the VTA (Larsson
et al 2005), and ACh-induced firing in VTA DA neurons can be potentiated by ethanol (Liu
et al 2013a). The increased concentration of ACh in the VTA could activate 6* nAChRs,
leading to the 6* nAChR-mediated increases in AMPAR function we report. Another
indirect, activity-dependent mechanism through which ethanol may contribute to reward
is by reducing GABAergic inhibition to VTA DA neurons (Di Chiara et al 1996, Spanagel et
al 1992). Although it is possible that ethanol and nAChR activation collaborate to enhance
AMPAR function via either of these mechanisms, we wanted to test the hypothesis that
ethanol increases AMPAR function by acting directly on DA neurons in an activityindependent manner. Therefore, we blocked action potential firing by pre-incubating
slices in TTX prior to and during the ethanol incubation. Our data shows that neuronal
activity is not required to enhance AMPAR function after ethanol exposure (Figure 4.1 E
and F). This strongly supports a direct mechanism of action on DA neurons rather than
the indirect, activity-dependent mechanisms discussed above. Prior studies support that
a direct activity-independent mechanism is possible. ACh that is released in VTA slices and
which contributes to baseline 6* nAChR activity is insensitive to TTX (Drenan et al 2008a).
Recently, Berg and colleagues reported a novel, cell-autonomous mechanism by which
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nicotine elicits enhanced AMPAR trafficking to the surface of hippocampal neurons (Halff
et al 2014). Our data showing that AMPAR function is enhanced even in the presence of
TTX (Figure 4.1 E and F) suggest that a similar cell-autonomous, 6-mediated effect could
also occur in VTA DA neurons.
6.6

The Combined Activity of Nicotine and Ethanol in Enhancement of AMPAR
Function

Our data demonstrating that subthreshold concentrations of nicotine and ethanol can
combine to enhance AMPAR function on the surface of VTA DA neurons (Figures 4.5 and
4.6) is consistent with previous reports showing simultaneous nicotine + ethanol coexposure is synergistic or additive (Clark & Little 2004, Liu et al 2013a, Liu et al 2013b,
Tizabi et al 2007, Tizabi et al 2002). Our demonstration that 100 nM nicotine plus 5 mM
ethanol combine to enhance VTA AMPAR function (Figure 4.5) is relevant to human
consumption of these drugs. A blood alcohol concentration of approximately 25 mg/dL
(0.025% or 5 mM) is achievable with one drink and would not be expected to produce
behavioral changes in humans other than mild euphoria and/or slight social disinhibition.
A nicotine plasma level of 100 nM is easily achievable by one cigarette in a person naïve
to nicotine (Henningfield 1995). In a daily smoker, this level of nicotine in plasma would
be attainable by afternoon or evening simply due to accumulation of the drug from
cigarettes smoked throughout the day (DHHS 1988). These properties of nicotine and
ethanol, taken together with our data suggest that, in humans, one drink plus one
cigarette may be sufficient to produce synaptic plasticity changes in VTA DA neurons that
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are relevant to the addiction process. Genetic evidence points to a prominent role for 6containing nAChRs in alcohol consumption as well as nicotine addiction (Hoft et al 2009a,
Hoft et al 2009b). Our data suggest that 6-containing nAChRs play a central role in the
response to subthreshold, co-applied concentrations of nicotine and ethanol via CtxMII
inhibition in non-Tg mice (Figure 4.5 B and C) and via selective activation in 6L9S mice
(Figure 4.6). In experiments involving DA release from striatal synaptosomes, CtxMIIsensitive (6-dependent) nAChRs are the most sensitive to nicotine (Salminen et al 2007),
supporting the notion that they are capable of responding meaningfully to subthreshold
nicotine when ethanol is present to enhance receptor activity. In further support of the
idea that 6-containing nAChRs confer the ability to respond to very low concentrations
of nicotine, 6KO mice have reduced tendency to self-administer low (10 ng)
concentrations of nicotine (Exley et al 2011).
Varenicline is a partial agonist with similar efficacy and potency at both CtxMII-sensitive
(6-containing) and CtxMII-resistant (non-6) nAChRs (Grady et al 2010). Varenicline is
thought to promote abstinence from smoking via a dual mechanism: 1) varenicline
substitutes for nicotine in activating nAChRs, and 2) varenicline competes with and blunts
the full action of nicotine in activating nAChRs (Rollema et al 2007). Our results suggest
that varenicline, similar to CtxMII, may interfere with the ability of nicotine and/or
ethanol to enhance AMPAR function in VTA neurons (Figures 4.5 and 4.6). This is
consistent with varenicline's action in preclinical and clinical studies. For example,
varenicline reduces ethanol intake in mice (Hendrickson et al 2010) and rats (Steensland
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et al 2007). Varenicline also reduces alcohol consumption in heavy drinking smokers
(Fucito et al 2011, McKee et al 2009, Mitchell et al 2012). Together, this suggests that
patients taking varenicline may be afforded some protection from the addictive
properties of subthreshold concentrations of nicotine + alcohol. Varenicline, or other
compounds with partial agonist properties at 4* and/or 6* nAChRs but a better side
effect profile, could be useful in attenuating nicotine/alcohol co-addiction.
6.7

Role of 4 nAChR Subunits in VTA DA Neuron Excitability

In addition to studying changes in glutamatergic synaptic plasticity in Chrna4 vMB cKO
mice (Figure 5.7), we also identified circuitry changes within the VTA. In our Chrna4 vMB
cKO mouse model, we interestingly saw enhanced excitability of VTA DA neurons (Figure
5.3). This may be counterintuitive based off previously published studies in 4KO mice.
One study found that activation of VTA DA neurons by nicotine is dependent upon 4*
nAChRs (Zhao-Shea et al 2011) and another study showed that while the baseline action
potential firing rate is the same in WT and 4KO mice, nicotine does not result in an
increase in the firing rate of VTA DA neurons in 4KO mice (Liu et al 2012). Likewise, we
saw no difference in the baseline firing rate (Figure 5.3). However, during current
injection steps we saw that, compared to Cre(-) VTA DA neurons from control Chrna4
loxP/loxP mice, Cre(+) VTA DA neurons from Chrna4 vMB cKO mice have a decreased first
interspike interval at lower current injections and increased firing rate over the whole two
second current injection step at higher current injections (Figure 5.3). We reasoned that
because in our model, 4 nAChR subunits can be removed from any cell type that
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expresses 4 nAChR subunits (Figure 5.1), that the enhanced excitability of DA neurons
was due to removal of 4 nAChR subunits on GABA neurons. Within the VTA, GABA
interneurons highly express 42* nAChRs (Klink et al 2001, Mansvelder et al 2002).
These GABAergic neurons also fire spontaneously (Steffensen et al 1998) and therefore
may tonically inhibit VTA DA neurons. Interestingly, picrotoxin administered into the VTA
results in increased DA release in the NAc (Ikemoto et al 1997a), suggesting that removal
of GABAergic signaling in the VTA excites DA neurons. Moreover, rats will self-administer
picrotoxin into the VTA (Ikemoto et al 1997b). Therefore, we looked at spontaneous IPSCs
in VTA DA neurons as a way to analyze changes in GABA release after removal of 4
nAChR subunits. We indeed did see a decrease in the instantaneous frequency of
spontaneous IPSCS in VTA DA neurons in Chrna4 vMB cKO mice compared to control
Chrna4 loxP/loxP mice that still have 4 nAChR subunit expression intact (Figure 5.4).
Spontaneous IPSC instantaneous frequency was also dramatically reduced in control
Chrna4 loxP/loxP mice in the presence of TTX, indicating activity of GABAergic neurons
within the VTA is important for GABA release (Figure 5.4 E).
Our results showing that removal of 4* nAChRs from the VTA decreases IPSC
instantaneous frequency implies GABAergic neurons are controlled by cholinergic
signaling. We hypothesize that ACh released onto GABAergic neurons acts on 42*
nAChRs and stimulates GABA release. This is plausible as the VTA receives cholinergic
input from the PPTg and LDTg (Mao & McGehee 2010) and endogenous ACh has
previously been shown to contribute to IPSCs in VTA DA neurons (Mansvelder et al 2002).
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Future experiments measuring the firing rate of VTA GABAergic interneurons in Chrna4
vMB cKO mice will provide further insight into cholinergic control of GABAergic neurons
within the VTA.
Therefore, our proposed mechanism for increased VTA DA neuron excitability is a
disinhibition mechanism as illustrated in Figure 5.8. We hypothesize that in control
Chrna4 loxP/loxP mice, afferents from the PPTg and LDTg release ACh in the VTA, which
activates 42* nAChRs located on GABAergic interneurons, and stimulates GABA
release. In Chrna4 vMB cKO mice, removal of 42* nAChRs from the VTA results in less
GABA released onto VTA DA neurons and removal of this source of tonic inhibition results
in enhanced VTA DA neuron excitability. In mice with hypersensitive 4* nAChRs
selectively expressed on GABAergic neurons, low doses of nicotine resulted in reward-like
behavior (Ngolab et al 2015). Because 42* nAChRs have been shown to rapidly
desensitize (Mansvelder et al 2002) this could be explained by a disinhibition mechanism
similar to what we propose is occurring in our study. However, the authors concluded
that desensitization is not responsible for reward due to their finding that DHE (a
moderately selective α4* nAChR antagonist) does not similarly lead to a nicotine
conditioned place preference (Ngolab et al 2015).
The VTA also receives GABAergic input from the nearby RMTg, also referred to as the tail
of the VTA (Barrot et al 2012). While we took measures to try to contain the virus to the
VTA and limit the spread to nearby regions through small injection volumes and the use
of the AAV2 serotype which diffuses less (Passini et al 2004), it is possible that 4 nAChR
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subunits may be removed from the RMTg as well. Therefore, we repeated our IPSC
recordings in Chrna4 loxP/loxP mice given injections of a retrograde Cre virus into the NAc
(Figure 5.6 A) and saw similar decreases in IPSC instantaneous frequency but not
amplitude (Figure 5.6 C-F). We still saw viral expression in both DA and non-DA neurons
within the VTA (Figure 5.6 B), indicating that both DA and GABA VTA neurons send
projections to the NAc. Furthermore, the recorded DA neuron itself does not have to
express the Cre virus in order to exhibit decreased IPSC instantaneous frequency in
Chrna4 vMB cKO mice, as long as the virus was indeed expressed in the VTA. This
indicates that some VTA GABA neurons send projections to both the NAc and VTA DA
neurons.
Further, we wanted to rule out the possibility that the enhanced excitability we see in
VTA DA neurons is due to increased glutamatergic signaling. Therefore we measured
spontaneous EPSCs (Figure 5.5). We saw no differences in either the instantaneous
frequency nor the amplitude in Chrna4 vMB cKO mice compared to control Chrna4
loxP/loxP mice with 4 nAChR subunits intact. This is consistent with a previous study
indicating that 7 nAChRs, not 4* nAChRs, are the primary nAChR subtype responsible
for glutamatergic release in the VTA (Mansvelder & McGehee 2000).
Our electrophysiology results showing enhanced excitability of VTA DA neurons is
consistent with locomotor data collected by a colleague also working with this mouse
model in our lab. Baseline locomotor activity of Chrna4 vMB cKO mice is significantly
higher compared to Chrna4 loxP/loxP control mice (unpublished result). DA levels in the
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NAc have not been measured in Chrna4 vMB cKO mice. However, our data showing
enhanced VTA DA neuron excitability and increased locomotor activity in Chrna4 vMB cKO
mice, is consistent with data showing that 4KO mice have increased basal levels of DA
in the NAc (Marubio et al 2003).
Our data highlights the importance of 4 nAChR subunit expression in the adult mouse
VTA in controlling the activity of VTA DA neurons. Developing mouse models where
removal of 4 nAChR subunits is targeted to specific cell types, DAergic neurons versus
GABAergic neurons, will provide further insight into the role of 4* nAChRs within the
VTA.
6.8

Future Directions

While we demonstrated the involvement of 6* nAChRs in nicotine-mediated AMPAR
enhancement on VTA DA neurons, more work still needs to be done to better understand
the downstream mechanism of AMPAR insertion.

Our results showing no inward

rectification suggest an increase in the number of AMPARs expressed on the cell surface.
On the other hand, when constructing concentration-response curves, we saw increased
AMPAR sensitivity. Rather than an increase in the number of AMPARs expressed on the
cell surface, an increase in AMPAR sensitivity suggests an exchange of AMPARs for those
with an increased conductance. Future studies should be done to better understand
which mechanism of AMPAR insertion occurs in VTA DA neurons following nicotine
exposure.

Experiments with pharmacological inhibitors that distinguish between

different AMPAR subtypes, such as philanthotoxin, could be performed to address this
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issue. Alternatively, looking at the kinases involved in AMPAR insertion could provide
insight into this mechanism. We show that CaMKII activity is necessary for increased
AMPAR function. Future experiments can be done to determine which AMPAR subunits
are phosphorylated and at what site following nicotine exposure.
When doing experiments with Chrna4 vMB cKO mice, we found that VTA DA neurons in
these mice are more excitable in response to depolarizing current injections than VTA DA
neurons in Chrna4 loxP/loxP control mice. Our method of removing 4 nAChR subunits
from Chrna4 loxP/loxP mice via Cre viral injections has the advantage of removing 4*
nAChRs from adult mice as well as from specific brain regions. However, 4 nAChR
subunits are removed from both dopaminergic neurons and non-dopaminergic neurons
within the VTA. Therefore, we cannot tell if 4 nAChR subunit removal from dopaminergic
neurons, GABAergic neurons, or a combination of the two is primarily responsible for the
enhanced excitability of VTA DA neurons in Chrna4 vMB cKO mice. Future studies
selectively removing 4 nAChR subunits from specific cell types will be useful to further
understand the circuitry within the VTA. Such experiments could be accomplished by
crossing mice that express Cre under the control of specific promoters with Chrna4
loxP/loxP mice. Drawbacks to this approach include the removal of 4* nAChRs globally
and during development.
We hypothesized that removal of 4* nAChRs decreased cholinergic excitation of
GABAergic neurons, resulting in decreased GABA release.

Additional experiments

recording the firing rate of GABAergic neurons could provide further support of our
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hypothesis in addition to our IPSC recordings from DA neurons. If our hypothesis is
correct, there will be a decrease in the spontaneous firing rate of GABAergic neurons in
Chrna4 vMB cKO mice. Finally, it would be of interest to see if 4* nAChR selective
antagonists, such as DHE could recapitulate the results we obtained with Chrna4 vMB
cKO mice.
While our results indicate that 6* nAChRs may play a crucial role in the development of
nicotine dependence, there are currently no drugs available to selectively target these
receptors without also acting on (non-6)4* nAChRs. Improvements in the ability to
stably, robustly express 6* nAChRs in heterologous systems would allow high
throughput screening to help identify selective molecules. Our results suggest such drugs
may be useful not only for tobacco cessation but also for treating alcoholism or tobacco
and alcohol co-abuse.
6.9

Conclusions

Overall, these studies highlight the importance of 46* nAChRs in the initiation of
cellular changes that play a role in addiction. Our data show for the first time that
activation of 462* nAChRs by nicotine is sufficient to stimulate a depolarizing
conductance in VTA DA neurons as well as enhance AMPAR function on the cell surface.
We also show involvement of 62* nAChRs in ethanol-mediated enhancement of
AMPAR function and demonstrate that ethanol and nicotine can combine to enhance
excitatory transmission in the mesolimbic DA pathway. While 6* nAChRs are expressed
solely on DA neurons in the VTA, 4* nAChRs are also expressed on GABA neurons where

123
we find they play an important role in controlling GABA release and therefore DA neuron
excitability. Together, our data show that 462* nAChRs are emerging as a key target
for smoking and alcohol cessation pharmacotherapies.
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